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Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1) has been 
widely implicated in the pathophysiology of chronic kidney disease (CKD) as well as 
the cardiovascular disease with which it is associated. ET receptor antagonists have 
favourable effects in experimental models of these conditions and orally acting 
antagonists are now licensed for the treatment of pulmonary arterial hypertension. 
However, there is a paucity of human data regarding the role of ET-1 in CKD. In this 
thesis, I have therefore explored the utility of ET-1 as a biomarker in CKD, and, using 
selective ET receptor antagonists, the beneficial renal and cardiovascular effects of ET 
receptor antagonism in CKD. 
 
I have shown that as glomerular filtration rate (GFR) declines plasma ET-1 increases 
linearly whereas urinary ET-1 shows an exponential increase. Furthermore, urinary ET-1 
may be a useful marker of disease activity in patients with lupus nephritis. Its levels are 
high in those with biopsy-proven active renal inflammation and these fall with treatment. 
 
I have shown that in subjects with stable non-diabetic proteinuric CKD, acute selective 
ETA receptor antagonism reduces blood pressure and arterial stiffness and that these 
systemic benefits are associated with an increase in renal blood flow and reduction in 
proteinuria. Importantly, these effects are seen on top of those achieved with maximal 
therapy with angiotensin converting enzyme inhibitors and/or angiotensin receptor 
blockers. 
 
Following a study confirming unchanged pharmacokinetics in CKD, I have used an oral 
selective ETA receptor antagonist to show that the reductions in BP, arterial stiffness and 
proteinuria seen in my acute studies are maintained longer term. This results of this 
study also suggest that the mechanism for the reduction in proteinuria is haemodynamic 
and relates to  a reduction in GFR and filtration fraction.  
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In summary, these studies suggest that ET-1 may act as a potential biomarker of renal 
inflammation, and confirm its role in the pathophysiology of the systemic and renal 
vasoconstriction seen in CKD. They also suggest that selective ETA receptor antagonism 
may provide a novel therapeutic approach in proteinuric CKD on top of standard 
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Chronic kidney disease (CKD) is common. A study in general practice has demonstrated 
that an elevated creatinine is present in 6% of hypertensives, 13% of diabetics and 17% 
of patients with both conditions1. A United States (US) population study suggests that 
more than 10% of the general adult population have an indicator of kidney damage − 
proteinuria, haematuria, and/or reduced glomerular filtration rate (GFR)2 and there is no 
reason to think that these figures will be substantially different in the United Kingdom. 
Despite our best current treatments, progression to end-stage renal disease (ESRD) 
remains a major clinical and financial problem and there are currently over a million 
patients worldwide on dialysis, with the number continuing to increase yearly.  
 
It is now well-recognised that cardiovascular disease (CVD) is strongly associated with 
CKD3, 4 and constitutes one of its major causes of morbidity and mortality4. Indeed, CKD 
has emerged as an important and powerful independent risk factor for CVD4. As GFR 
declines the risk of CVD increases and patients with non-dialysis-requiring CKD are 
more likely to die from CVD than develop ESRD4. Furthermore, not only are individuals 
with CKD at increased risk of cardiovascular events but their outcome is worse than in 
those without CKD5. Although the prevalence of traditional risk factors (such as 
diabetes, hypertension, dyslipidaemia) in the CKD population is high, CVD events 
remain disproportionate to the underlying risk factor profile4. Thus, ‘non-traditional’ risk 
factors, such as endothelial dysfunction, arterial stiffness, oxidative stress and 
inflammation, which may contribute to this excessive uraemic cardiovascular risk, have 
become a major focus of interest. 
 
Thus, there is an important unmet need for treatments that not only slow the rate of 
progression of renal impairment, delaying the onset of dialysis in CKD, but also that 
might improve the cardiovascular risk profile in these patients. Blockade of the 
endothelin (ET) system has emerged as one potential strategy. The ET system has been 
widely implicated in renal disease, including acute renal failure6 and emerging data 
suggest that inhibition of its actions might slow the progression of CKD and reduce the 
burden of CVD with which it is associated. 
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Biology of the endothelin system 
First described by Yanagisawa in 19887, ETs are a family of 21 amino acid peptides with 
powerful vasoconstrictor and pressor properties. Three different isopeptides, ET-1, ET-2 
and ET-3, are known, each with distinct genes and tissue distributions7-9. ET-1 is the 
major endothelial isoform and, in the human kidney, the only one so far shown to be 
expressed at the protein level10. Its main site of vascular production is the endothelial 
cell but it is also produced by other cell types including vascular smooth muscle cells 
and epicardial cells11. Within the kidney, it is produced by glomerular epithelial and 
mesangial cells, and renal tubular and medullary collecting duct cells6. Furthermore, the 
renal medulla is not only an important site of ET-1 generation but also contains among 
the highest concentrations of immunoreactive ET-1 of any organ12. 
 
The gene product is the 212 amino acid pre-pro-ET-1, and regulation of ET synthesis 
occurs at the level of gene transcription. Enhanced generation occurs with a wide range 
of stimuli13, 14 (Figure 1.1). Those pertinent to CKD include other vasoactive hormones, 
such as angiotensin (ANG II) and vasopressin (AVP), the cytokine interleukin (IL)-1, 
oxidised LDL, reduced extracellular pH, and cyclosporin A (CyA). In contrast, 
prostacyclin, nitric oxide (NO), and the natriuretic peptides all inhibit gene transcription. 
Pre-pro-ET-1 is cleaved to big ET-1 (38 amino acids) which is largely biologically 
inactive15. Endothelin converting enzyme (ECE) then catalyses generation of the 
biologically active ET-1 and C-terminal fragment from big ET-1. Once synthesised, the 
secretion of mature ET-1 from endothelial cells is largely abluminal16, towards the 
adjacent vascular smooth muscle, suggesting an autocrine or paracrine action. 
 
Figure 1.1 (overleaf): Pathways of endothelin-1 (ET-1) synthesis and sites of action. 
ANP: atrial natriuretic peptide, BNP: brain natriuretic peptide, IL-1: interleukin-1, TGF-









ET-1 acting in the vascular system 
ET-1 acts by binding to two receptors, the ETA and ETB receptor17, 18 (Table 1.1). Within 
blood vessels, ETA receptors are found on smooth muscle cells and their activation 
results in vasoconstriction. ETB receptors are also found on vascular smooth muscle 
cells19, where they can mediate vasoconstriction, but are predominantly found on the 
vascular endothelium where their activation results in vasodilatation via prostacyclin and 
NO20. 
 
In addition, the ETB receptor also acts as a clearance receptor for circulating ET-1. The 
half-life of ET-1 in the healthy circulation is ~1 min21 with removal through receptor and 
non-receptor mediated mechanisms. ET-1 binds to ETB receptors, with subsequent 
ligand-receptor complex internalisation and intracellular degradation accounting for the 
majority of clearance, particularly in the pulmonary circulation22, though the splanchnic 
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and renal circulations also contribute13. Therefore, reductions in ETB numbers, or ETB 
receptor blockade, may reduce ET-1 clearance, increasing plasma concentrations 
without altering production. Importantly, because most ET-1 is released abluminally, 
plasma concentrations of ET-1 do not accurately reflect ET-1 production. 
 
ET-1 acting in the renal system 
ET receptors are widely distributed within the human kidney, with the ETA subtype 
localised to vascular smooth muscle, notably in the glomeruli, vasa recta and arcuate 
arteries, whereas ETB receptors are more numerous (ETB to ETA ratio 2:1), and more 
widespread, with a high concentration in the collecting system10, 23. With respect to the 
renal system, ET-1 has a role in the paracrine/autocrine regulation of renal and intrarenal 
blood flow, glomerular hemodynamics, sodium and water homeostasis24, and acid-base 
balance25 (Table 1.1). It is also clear that ET-1 has many other functions within the 
kidney26. Evidence exists for renal and vascular ET-1 acting as two independent 
systems27. After systemic infusion of radiolabelled ET-1, labeled compound makes up 
less than 1% of total urinary ET-128. Therefore, neither glomerular filtration nor tubular 
secretion of plasma ET-1 accounts for urinary ET-1, which is therefore assumed to be 




Table 1.1: Actions of endothelin-1. The table shows the receptor responsible for each 
action but, particularly in the case of the ETA receptor-mediated actions, does not 




Defining the role of endothelin in physiology 
ET-1 is a potent vasoconstrictor in vitro, and pressor in whole animals29. With respect to 
the kidney, exogenous ET-1 causes renal vasoconstriction30. Indeed, the renal 
vasculature is more sensitive to the vasoconstricting effects of ET-1 than other vascular 
beds31. Although exogenous ET-1 reduces total renal blood flow (RBF), a regional 
difference has been observed, with cortical vasoconstriction32-34 and NO dependent 
medullary vasodilatation32. Exogenous ET-1 has also been shown to cause constriction 
of afferent and efferent arterioles, with a greater effect on the former35, and reduce 
filtration coefficient by mesangial cell contraction26. In man, a similar vasoconstrictor15 
and pressor response has been demonstrated36, as well as renal vasoconstriction, a fall in 
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total RBF and a consequent reduction in GFR37. As yet, there are no studies of the 
effects of ET-1 on intra-renal distribution of blood flow in man.  
 
With respect to renal tubular functions, there is now a substantial body of evidence 
supporting a role for ET-1 in the regulation of volume homeostasis. ET-1 inhibits the 
vasopressin (AVP) stimulated retention of water in inner medullary collecting duct cells 
(IMCD) in vitro38, and extra-cellular sodium concentrations may regulate IMCD ET-1 
production24, 39. Additionally, ET-1 appears to have a natriuretic role, at least in animals. 
ET-1, acting via ETB and NO, can inhibit chloride transport in the medullary thick 
ascending limb of Henlé, thus promoting natriuresis40, 41. Picomolar ET-1, binding to ETB 
receptors, activates amiloride-sensitive sodium channels in distal tubular cells in vitro, 
though higher, nanomolar doses inhibit this channel by a non-ETB receptor dependent 
mechanism42. This has been supported by in vivo experiments in rats demonstrating 
natriuresis due to reduced sodium transport in the proximal and distal nephron segments 
in response to low dose exogenous ET-1 with higher doses resulting in sodium retention 
due to glomerular vasoconstriction43.  
 
Agonist studies may not adequately represent the effects of a hormone the actions of 
which are largely autocrine/paracrine, and inhibition of the production or actions of ET-
1 may better define its physiological and pathological effects. In this respect, ET 
receptor antagonists have proved to be useful tools in defining the role of ET in health 
and disease. ET receptor antagonists are classified as ETA selective (such as the iv 
antagonist BQ-123), or ETB selective (such as the iv antagonist BQ-788), depending on 
their relative affinity for a receptor subtype, or non-selective (such as the oral drug, 
bosentan)13. It should be noted, however, that the distinction between selective and non-
selective antagonists is not pharmacologically well-defined. The so-called ‘non-
selective’ antagonists are still selective for the ETA receptor, but the ratio of ETA to ETB 
affinity is generally 10-100-fold selective for ETA over ETB, compared to 1000-fold or 
more for recent ETA selective agents13. 
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With respect to systemic haemodynamics in healthy man, selective ETA receptor 
antagonism is associated with vasodilatation44 and a reduction in blood pressure (BP)45, 
and selective ETB receptor antagonism with vasoconstriction44 and a pressor response46. 
This suggests that endogenous ET-1 contributes to the maintenance of vascular tone and 
BP via the ETA receptor, and the balance of ETB receptor function favors activation of 
the endothelial over the vascular smooth muscle ETB receptor.  
 
In the kidney, animal studies have suggested that both exogenous and endogenous ET-1 
mediated reductions in total RBF are mediated via the ETA receptor47, 48. Antagonist 
studies describe cortical vasoconstriction as ETA receptor mediated and medullary 
vasodilatation as ETB receptor mediated32, 33, 47. Furthermore, in vitro studies have shown 
that combined ETA/B receptor antagonism is required to fully abrogate the 
vasoconstricting effects of exogenous ET-1 on the afferent arteriole suggesting that both 
ETA and vascular smooth muscle cell ETB receptors are involved. At the efferent 
arteriole the effect of ET-1 is blocked by ETA receptor antagonism alone, and enhanced 
by ETB receptor blockade, suggesting that ET-1 can modulate efferent arteriolar tone via 
the ETA receptor and that the balance of ETB receptor effects here is to produce 
vasodilatation35. The situation is less clear in healthy humans where there are few 
studies. One study has demonstrated an increase in RBF after non-selective ET receptor 
blockade49. Most, however, do not demonstrate an effect of selective ETA receptor 
blockade, or combined ETA/B receptor blockade, on basal renal haemodynamics50-53, 
suggesting that ET-1 acting via the ETA receptor does not contribute to the maintenance 
of renal vascular tone in health. Selective and unopposed ETB receptor antagonism can, 
however, produce profound renal vasoconstriction, suggesting that ET-1 mediated tonic 
renal vasodilatation via the ETB receptor is important. 
 
Studies have suggested a natriuretic role for the tubular ETB receptor which is linked to 
NO generation. A potent inhibitory action of NO on tubular sodium reabsorption is well 
described54. A rat model deficient in renal ETB receptors displays a salt-sensitive 
hypertension, with restoration of normal BP by amiloride, suggesting that the ETB 
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receptor regulates sodium excretion at the epithelial sodium channel in collecting duct 
(CD) cells55, and ETB antagonist-treated rats develop a sodium-dependent hypertension56. 
Additionally, in the face of acute ETB receptor blockade, pressure-natriuresis curves are 
shifted to the right such that a greater renal perfusion pressure is needed to excrete the 
same amount of sodium57. Finally, administration of exogenous low dose ET-1 to dogs 
in the presence of high grade selective ETA receptor blockade results in renal 
vasodilatation and natriuresis, presumably by unmasking an ETB receptor mediated 
effect58. Dissecting the different actions of the intrarenal ET system has however proved 
difficult, in part from an inability to discriminate between effects of ET-1 in vivo on the 
nephron and vasculature. To date, ET-1 associated natriuresis and diuresis have not been 
demonstrated in man. 
 
Defining the role of endothelin in pathophysiology 
Hypertension 
Initial evidence of a pressor action of ET-1 led to the suggestion that ET-1 might be 
implicated in hypertension7. Production of vascular ET-1 is increased in some (such as 
the Dahl salt-sensitive and the stroke-prone spontaneously hypertensive rat (SHR)), but 
not all animal models of hypertension59. Those models where ET-1 production is 
increased (mostly, but not exclusively salt-dependent types) are associated with 
increased vascular growth and a response to both selective and non-selective ET 
receptor antagonism comprising not only a modest reduction in BP but also a marked 
regression of vascular growth59.  
 
In man, ET-1 message and protein are increased in the vascular smooth muscle cells of 
hypertensive patients60. Elevated plasma ET-1 concentrations, however, are not a 
consistent finding59. High concentrations would appear, mostly, to be a feature of severe 
hypertension or indicative of the presence of complications or co-existing disease. 
Some61, but not all62 local studies with ET receptor antagonists suggest increased 
vascular ET system activity in patients with hypertension compared to normotensive 
controls, and a greater forearm vascular response to non-selective receptor antagonism 
 24 
compared to selective ETA antagonism, consistent with an increased importance of 
vascular smooth muscle vasoconstrictor ETB receptors in hypertension. In CKD, local 
administration of BQ-123 increases forearm blood flow63. Systemic administration of 
BQ-123 (+/- BQ-788) to hypertensive patients with CKD showed that selective ETA 
receptor blockade produces a substantial reduction in BP (∼10mmHg), whereas non-
selective ETA/B receptor antagonism lowered BP to a lesser extent. In both cases, the 
reduction in BP was much greater than in healthy controls64, supporting an upregulation 
of the ET-1 system in CKD-associated hypertension. Only one major study has 
examined the longer-term anti-hypertensive effects of ET receptor antagonism in man. 
Bosentan, an orally available, non-selective ET receptor antagonist reduced BP in 
essential hypertensives as much as did enalapril 20mg65. Importantly, this reduction was 
achieved without activation of the sympathetic nervous or renin-angiotensin system 
(RAS).  
 
Altered intrarenal ET-1 production may contribute to hypertension66, 67. SHR have 
reduced medullary ET-1 levels after the development of hypertension68. More recently, 
Kohan et al have successfully created an elegant tissue-specific knockout of the renal ET 
system. Mice lacking CD expression of the ET-1 gene have reduced urinary ET-1. These 
animals are hypertensive and have an impaired ability to excrete a sodium load67. 
Interestingly, these knockout mice excrete acute water loads less well than wild-type 
mice, and have a heightened physiological response to AVP, consistent with an intra-
renal role for ET-1 in blunting the response to AVP69. While plasma ET-1 concentrations 
are normal, urinary ET-1 excretion is reduced in hypertensive subjects compared to 
healthy controls suggesting that either renal ET-1 synthesis is reduced or breakdown is 
enhanced70, 71. Thus, renal ET-1 production or handling may be altered in hypertension, 
leading to inappropriate sodium and water retention, and aiding the development and/or 
maintenance of hypertension. 
 
Renal function may also influence the relationship between ET-1 and hypertension. 
Firstly, as renal function declines plasma ET-1 levels increase71, 72. The effects of 
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exogenous ET-1 on the renal vasculature are to cause vasoconstriction, activating the 
RAS and causing salt and water retention, both of which have the potential to raise BP. 
It remains to be seen whether the rise in ET-1 concentrations seen in CKD is due to 
biologically-active or simply immunologically-competent peptide, but infusion of 
exogenous ET-1 to bilaterally nephrectomised rats results in an increased plasma half-
life of ET-1 and a prolonged rise in BP compared to sham-operated rats73, consistent 
with the idea that elevated plasma ET-1 concentrations in CKD may cause hypertension. 
Second, there is an upregulation of renal ET-1 in CKD74, as reflected by increased 
urinary ET-1 excretion71. Third, there is a suggestion from an experimental model of 
nephritis associated with mesangial proliferation that the renal vasculature in this disease 
may be more sensitive to the vasoconstrictor effects of ET-1 than in normal kidneys75. 
Thus, an amplification of the renal vasoconstrictor effects of ET-1, promoting 
hypertension, could be envisaged in CKD. 
 
Studies of ETB receptor knockout animals suggest the ETB receptors are important in 
protecting against hypertension. These animals exhibit a sodium-dependent hypertension 
attributed to an absence of tonic inhibition of the epithelial sodium channel in the distal 
nephron55. Interestingly, ETB receptor deficient mice show renal injury, an impaired 
ability to excrete a sodium load and hypertension that persists when they are cross-
transplanted with wild-type kidneys suggesting that it may not only be renal but also 
extra-renal ETB receptors that play a protective role against hypertension76. 
 
Endothelial dysfunction and atherosclerosis 
The endothelium is a crucial regulator of vascular tone77 and its function is impaired, 
both in hypertension and in groups at risk of hypertension, with a shift towards reduced 
vasodilatation, associated with a pro-inflammatory and pro-thrombotic state. Endothelial 
dysfunction (ED) is also a well-recognised feature of CKD77. ED is recognised to be a 
key early determinant in the progression to atherosclerosis, and is now well established 
to be independently associated with increased cardiovascular risk78. Mechanisms that 
participate in ED include reduced NO generation, oxidative stress and upregulation of 
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inflammatory mediators77. Animal models of ED across a number of animal species have 
shown that antagonism of the ET system, predominantly with selective ETA receptor 
antagonists, improves NO-mediated endothelial function79-81, suggesting that ET-1, 
acting via ETA receptors, is involved in the pathogenesis of ED. Treatment with selective 
ETA receptor antagonism also improves endothelial function in the coronary vessels of 
patients with atherosclerosis, again suggesting that ET-1, acting via ETA receptors, is 
involved in the pathogenesis of ED in these patients82.  
 
The ET system is also implicated in the development of atherosclerosis. In smooth 
muscle cells and foamy macrophages in atherosclerotic models both ETA and ETB 
receptors are highly expressed83. Increased expression of ET-1 and ECE is seen in 
human arteries at different stages of atherosclerosis60, 84, and high levels of ET-1 have 
been found in human atherosclerotic lesions60, 84-86. Furthermore, plasma ET-1 
concentrations correlate positively with the degree of atherosclerosis present85. 
Importantly, not only is restoration of the impaired activity of the NO system, and hence 
improvement in endothelial function, seen following ET receptor antagonism in a range 
of animal models of atherosclerosis79, 80, 83, but so too is a reversal of atherosclerotic 
lesion development. Thus, ET antagonists reduce the activity of the ET system, increase 
NO bioavailability, improved endothelial function, and slow the progression of 
atherosclerosis. To date, there are no therapeutic studies on endothelial function or 
atheroma progression with ET antagonism in CKD patients. 
 
Arterial stiffness 
Arterial stiffness is an important independent predictor of all-cause and cardiovascular 
mortality in patients with ESRD87. Moreover, a therapeutic trial in ESRD patients by 
Guerin et al88 has shown that after BP reduction, cardiovascular survival was observed 
mainly in those patients who also displayed a reduction in arterial stiffness88. 
Epidemiologic studies indicate that there is increased cardiovascular risk early on in 
CKD, but there are as yet few data that show how early arterial stiffness develops89. 
Increased arterial stiffness results in a selective elevation of pulse pressure causing 
 27 
deleterious consequences for the heart. Through an elevation of central systolic BP, 
arterial stiffness enhances left ventricular load, favoring development of cardiac 
hypertrophy, and through reduction of central diastolic BP it decreases coronary 
perfusion pressure, contributing to myocardial ischaemia90. 
 
Arterial stiffness is linked to ED90 and the two conditions commonly co-exist in patients 
at increased risk of CVD. A number of interventions that reduce arterial stiffness also 
improve endothelial function90. To date, there have been few studies addressing the 
relationship between these two markers of CVD after treatment, and none in patients 
with CKD. However, there is now evidence from both animal and human studies that the 
endothelium is an important regulator of arterial stiffness. Basal endogenous NO 
generation decreases arterial stiffness in animals91 and humans92-94. By contrast, ET-1, at 
concentrations similar to those observed in the plasma of CKD patients, caused an 
increase in arterial stiffness that can be blocked by concomitant administration of an ETA 
receptor antagonist95. Furthermore, endogenous ET-1 has recently been shown to 
increase arterial stiffness96. Thus, in ED, where NO is downregulated and ET-1 
upregulated, the balance will likely shift in favor of increased arterial stiffness. Clinical 
studies of the effects of ET receptor antagonism on arterial stiffness in CKD will clearly 
be of great interest.  
 
Oxidative stress and inflammation 
Oxidative stress and inflammation are well documented in ESRD97, 98. Indeed they are 
very common even with mild renal insufficiency99. Oxidative stress is characterised by 
an imbalance between exposure to free radicals, principally derived from oxygen, and 
antioxidant defenses. As in ED, there is loss of NO availability in states of oxidative 
stress, and the close relationship between increased oxidative stress, reduced NO 
availability and subsequent cardiovascular events is well-established100. Additionally, 
there is now mounting evidence, although scarce human data, supporting the hypothesis 
that at least some of the injurious effects of ET-1 on the vasculature are mediated via an 
increase in oxidative stress, and that ET system blockade may be of use in reducing 
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this101, 102. Indeed, in DOCA-salt hypertension the ET-1 promoted production of reactive 
oxygen species (ROS), the principal mediators of oxidative stress, is ETA receptor 
mediated, and selective ETA receptor blockade normalises the ED found in this model103, 
independent of changes in BP. Data in CKD are scarce at present and it remains unclear 
whether oxidative stress is a cause or consequence of renal insufficiency. 
 
ROS likely promote the development of atherosclerosis through a number of 
mechanisms104, including ED, increased production of pro-inflammatory cytokines, such 
as IL-6, and acute phase proteins, such as C-reactive protein (CRP)105. IL-6 and CRP are 
both independent predictors of cardiovascular events and mortality106. Recent evidence 
suggests that a reduction in kidney function per se may be associated with an 
inflammatory response both in mild107 and advanced108 kidney disease, and a number of 
studies have shown that CRP predicts all-cause and cardiovascular mortality in dialysis 
patients109. In addition to being an important prognostic marker for CVD, CRP may 
contribute to the atherosclerotic process mainly through the impairment of endothelial 
function110, 111. Furthermore, CRP has been shown to decrease the activity of the NO 
system112 and to potentiate the release of ET-1105. Recently, ET receptor antagonism has 
been shown to attenuate the pro-atherogenic effects of CRP in vitro105, consistent with 
anti-inflammatory and anti-atherogenic actions. 
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Defining the role of endothelin in renal pathophysiology 
CKD & Renal Haemodynamics 
There are only few studies in animal models of CKD. Nevertheless, these show that ET 
receptor antagonism improves renal blood flow (RBF) and preserves GFR. Non-
selective ETA/B receptor antagonism with bosentan can prevent the renal vasoconstriction 
seen in the early phases of streptozocin-induced diabetes mellitus113 and selective ETA 
receptor antagonism can preserve GFR and RBF during acute114 and chronic CyA 
administration115. Additionally, in the Dahl salt-sensitive hypertensive rat, where a 
reduced RBF and GFR are observed after a high salt diet, systemic ETA/B receptor 
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antagonism tended to increase, and intra-renal interstitial infusion significantly 
increased, RBF and GFR116. 
 





In patients with CKD, selective ETA receptor antagonism produces an increase in RBF 
and decrease in renovascular resistance64, suggesting that ET-1 acting via ETA receptors 
is involved in the increased renovascular tone. These changes are accompanied by a fall 
in effective filtration fraction (EFF), suggesting that ET-1, acting via ETA receptors, 
exerts a preferential efferent arteriolar vasoconstrictive effect, raising the possibility that 
ET-1 promotes hyperfiltration with its consequent potential for renal injury. The renal 
haemodynamic effects of selective ETA receptor antagonism can be abolished by 
concomitant administration of an ETB receptor antagonist, and, as in health, selective 
blockade of the ETB receptor produced renal vasoconstriction64. Notably, in these 
studies, selective ETB receptor antagonism increased renal vascular resistance by twice 
as much (~20-30%) as systemic vascular resistance (~10-15%), suggesting that tonic 
ETB receptor mediated renal vasodilatation plays a key role in opposing renal 
vasoconstriction. This is likely to be of particular importance in CKD, where baseline 
renal vascular resistance is high. The renal haemodynamic changes in these studies are 
consistent with other work in CKD patients where non-selective ET receptor blockade 
reduces EFF whilst maintaining GFR56, and in diabetics with albuminuria, in whom 
selective ETA receptor antagonism reduced both BP and urinary protein excretion117, 118  
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Proteinuria 
Significant proteinuria has emerged as a powerful predictor of renal disease 
progression119, and proteinuria reduction is an important strategy to retard or prevent 
renal functional loss119, 120. Additionally, proteinuria is no longer simply a renal risk 
factor. Alongside the concept of CKD as a global vascular disease state is emerging the 
global cardiovascular risk associated with proteinuria. Albuminuria is incrementally 
associated with increased cardiovascular risk in both individuals with pre-existing risk 
(such as hypertensive patients)121, and in individuals with no known risk factor122. This is 
true even in the presence of normal renal function123. Furthermore, at least in 
hypertension, reduction of albuminuria confers cardiovascular protection121. 
 
Upregulation of the renal ET system exacerbates proteinuria. Through its haemodynamic 
effects ET-1 causes glomerular capillary hypertension, an increase in glomerular 
permeability and excessive protein filtration124. A reduction in microalbuminuria in 
patients with diabetes mellitus has recently been shown following chronic selective ETA 
receptor blockade117, 118. Furthermore, the reductions in EFF observed following acute 
selective ETA receptor antagonism in patients with CKD were accompanied by a 
reduction in proteinuria64 suggesting that one mechanism for the anti-proteinuric effect 
of ETA receptor antagonism in CKD may relate to alterations in glomerular 
haemodynamics with, potentially, a fall in glomerular capillary perfusion pressure. This 
would produce a situation analogous to that seen with angiotensin converting enzyme 
(ACE) inhibitors119, in which case ET antagonists might be expected to be renoprotective 
and improve long term renal outcome.  
 
The development of proteinuria is also associated with damage to the renal podocyte125, 
the highly specialised glomerular epithelial cell that helps maintain an intact filtration 
barrier under normal conditions. Recent in vitro studies suggest that podocytes undergo 
phenotypic changes that resemble de-differentiation as a result of exposure to exuberant 
amounts of protein126. In parallel with these changes there was increased ET-1 
production by the podocyte, which was, at least partly, dependent on the cytoskeletal 
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rearrangements brought about by excess protein exposure. In the same model, 
administration of exogenous ET-1 brought about similar podocyte cytoskeletal changes. 
Thus, the authors conclude that podocyte-derived ET-1 acting in an autocrine and 
paracrine manner promotes further podocyte ultrastructural degeneration and hence its 
own production, both of these contributing to a further breakdown in the glomerular 
filtration barrier. These data are in line with in vivo evidence in a murine model of 
protein overload that displays increased renal ET-1 production alongside the 
development of podocyte structural damage127.Whether damage to the podocyte is the 
primary event leading to subsequent proteinuria or vice versa remains unclear. 
Nevertheless, it is not unreasonable to envisage a series of events, with initial ET-1 
mediated glomerular hypertension exposing podocytes to unusually large amounts of 
protein and so leading to their de-differentiation and production of ET-1. This podocyte-
derived ET-1 could then exacerbate glomerular hypertension and lead to further 
podocyte de-differentiation so setting up a vicious cycle.  
 
Clinical studies are supportive of a role for the ET system in proteinuric nephropathies. 
Patients with chronic glomerulonephritis and proteinuria displayed a rise in renal ET-1 
and tubular ETB receptor expression that increased with higher degrees of proteinuria128, 
and patients exposed to selective ETA receptor antagonism both in the acute64 and 
chronic118 setting showed a significant reduction in proteinuria. 
 






Excess protein filtration at the glomerulus leads to increased tubular reabsorption. This 
can activate tubular-dependent pathways of interstitial inflammation and fibrosis, with 
progressive renal scarring129. Studies suggest a link between upregulation of the renal ET 
system and tubular protein reabsorption. Exposure of proximal tubular cells in vitro to a 
protein load leads to a dose-dependent increase in ET-1 production130. This phenomenon 
is not exclusively associated with albumin but may be seen with other proteins such as 
IgG and transferrin130. Within the interstitium, ET-1 has the capacity to bind to 
interstitial fibroblasts and promote their proliferation, and the generation of extracellular 
matrix (ECM)131. Furthermore, ET-1 is chemotactic for blood monocytes132 leading to 
secretion of pro-inflammatory cytokines and growth factors, events that could contribute 
to interstitial remodeling and scarring. Hence, a potential pathway may be envisaged 
whereby ET-1 could link proteinuria to interstitial fibrosis. 
 
In the remnant-kidney model, renal ET-1 gene expression and urinary ET-1 excretion 
correlate with degree of proteinuria and extent of renal damage74. Also, transgenic 
animal studies in which renal ET pathways are upregulated display renal tubulo-
interstitial lesions independent of changes in BP133. These BP-independent effects of ET 
are supported by antagonist studies where ET receptor antagonists lead to a slowing of 
progressive renal damage, even in the absence of BP modification134. Non-selective 
ETA/B receptor antagonism can reduce the increase in collagen and ECM deposition seen 
in rats treated with L-NAME, an inhibitor of NO synthesis, independent of BP changes, 
and can also reduce collagen I gene activity to normal levels, suggesting that ET-1 
promotes renal fibrosis via activation of this gene135. ET receptor antagonists have also 
been shown to attenuate the progression of renal insufficiency in a rat remnant-kidney 
model136. While non-selective ETA/B receptor antagonists have produced positive 
results137, the effect is greater with selective ETA receptor antagonism138. Indeed, 
concomitant administration of an ETB receptor antagonist can abolish the beneficial 
effects of ETA receptor antagonism139. In patients with nephrotic syndrome due to focal 
and segmental glomerulosclerosis, plasma and urinary ET-1 concentrations are 
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significantly higher than in healthy controls140, and nephrotic patients who show a 
reduction in proteinuria with immunosuppressive therapy also show reductions in 
urinary ET-1 excretion141. 
 
Blockade of the endothelin & renin-angiotensin systems: a potential synergism 
ET-1 and ANG II are powerful vasoconstrictors involved in the regulation of vascular 
tone, and there is considerable evidence for an interaction between the ET and RAS142. 
ANG II increases ET-1 transcription and secretion in vitro in a variety of cell types, 
including endothelial and vascular smooth muscle cells143, 144. ACE inhibitors also reduce 
renal ET-1 formation. Rats with reduced renal mass show a parallel fall in proteinuria, 
vascular and glomerular pre-pro-ET-1 mRNA, and ET-1 peptide, following RAS 
blockade with losartan and captopril145. Chronic ACE inhibitor treatment in animal 
models of glomerulosclerosis146 and immune-mediated glomerulonephritis147 leads to a 
reduction in proteinuria as well as a fall in renal ET-1 mRNA and protein expression.  
 
Interestingly, animal data have suggested that concomitant acute blockade of the RAS 
and ET system produces greater haemodynamic changes than those seen with blockade 
of either system alone148-152. Also, many clinical studies using ET receptor antagonists, in 
patients with heart failure, demonstrate major additional haemodynamic effects153, 154 in 
patients already receiving ACE inhibitors. Synergism in respect of acute systemic 
haemodynamic effects between ETA receptor antagonists and angiotensin receptor type 1 
antagonists (ARBs)52, or ACE inhibitors155 has been demonstrated in man. More 
recently, the combination of ET receptor antagonism and ACE inhibition has also been 
shown to improve endothelial function156, 157. 
 
In respect of the kidneys, when ETA receptor antagonism is given in the presence of 
ACE inhibition in healthy subjects, contrary to a lack of effect of ETA receptor 
antagonism alone, an increase in renal blood flow and natriuresis is observed, an effect 
which appears to be both ETB dependent and NO mediated155. While it is tempting to 
attribute the increase in sodium excretion to the activity of an unblocked tubular ETB 
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receptor, it is possible that the natriuresis is entirely a consequence of the renal 
vasodilatation and so essentially a haemodynamic effect. This would likely be the case if 
the intrarenal changes in RBF, of an ETB mediated increase in medullary blood flow, 
seen in animal models also occur in man. Further human studies are needed to 
characterise the role of the renal ETB receptor and the interaction between ET and ANG 
II in CKD, in which there is increased activity in the RAS, and in a setting where many 
patients are already treated with ACE inhibitors. 
 
Endothelin antagonism as a treatment strategy in CKD 
ET-1 plays a role in the maintenance of BP and arterial stiffness. It also contributes to 
endothelial dysfunction, oxidative stress and vascular inflammation. In animals, ET 
receptor antagonists have been shown to reduce BP, improve arterial stiffness and 
endothelial dysfunction, and retard the progression of atherosclerosis. Some of these 
observations are confirmed by clinical studies. However, studies in CKD are fairly 
limited but suggest that, in addition to having a beneficial effect on systemic 
haemodynamics, ET receptor antagonists improve renal function and may potentially 
reduce renal disease progression.  
 
The question of whether selective or non-selective receptor blockade should be used is 
probably disease-specific, and in CKD remains to be clarified. However, preliminary 
evidence in patients with CKD suggests that both selective ETA and non-selective ETA/B 
receptor blockade reduce BP but that selective ETA blockade has additional desirable 
effects on renal haemodynamics64. From the current evidence base, concomitant ETB 
receptor blockade seems at best to offer no advantage over selective ETA antagonism 
and may potentially reduce the benefits. Further studies are needed to discern the 
theoretical beneficial effects of an unblocked ETB receptor in terms of natriuresis, 
diuresis and glomerular haemodynamics. Additionally, more clinical data are essential to 
advancing our broader understanding of the role of ET receptor antagonism, not only as 
a potential renoprotective therapy in CKD, but also as a treatment for the CVD with 
which it is associated. 
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Aims and hypotheses 
In a series of acute and chronic studies this thesis explores the role of ET-1 and its 
antagonism in CKD. 
 
Study 1 (Chapter 3): This study investigated the impact of progressive renal 
dysfunction and renal inflammation on plasma and urinary ET-1 concentrations. We 
hypothesised that plasma and urinary ET-1 concentrations would increase as GFR 
declined, and that in subjects with varying degrees of inflammatory CKD, but normal 
renal function, urinary ET-1 would act as a surrogate measure of the underlying renal 
inflammation. 
 
Study 2 (Chapter 4): Here we studied the effects of acute selective ETA receptor 
antagonism on BP, proteinuria and renal haemodynamics, arterial stiffness and 
endothelial function in patients with proteinuric CKD. We hypothesised that selective 
ETA receptor antagonism would reduce BP and proteinuria, and additionally reduce 
arterial stiffness and improve endothelial dysfunction. We expected these effects to be 
evident on top of standard treatment with blockers of the renin-angiotensin system. 
 
Study 3 (Chapter 5): To inform our studies in Chapter 6, here we investigated the 
pharmacokinetic profile of a single 100 mg oral dose of sitaxsentan, a selective ETA 
receptor antagonist, in subjects with normal and impaired renal function. Since over 
50% of the administered dose of sitaxsentan is excreted via the kidneys, impaired renal 
function could potentially affect the pharmacokinetics of sitaxsentan.  
 
Study 4 (Chapter 6): Our acute studies (Chapter 4) showed that acute selective ETA 
receptor antagonism reduces proteinuria, BP and arterial stiffness - key independent, 
surrogate markers of CKD progression and CVD risk, in patients with proteinuric CKD. 
These studies therefore examined if these effects are maintained longer term using the 
selective ETA receptor antagonist sitaxsentan. 
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Chapter 2  
 




All studies were performed in the University of Edinburgh’s Clinical Research Centre 
with the approval of the local research ethics committees and the written informed 
consent of each subject. The investigations conformed to the principles outlined in the 
Declaration of Helsinki.  
 
All subjects abstained from alcohol, nicotine and caffeine-containing products for 24 
hours, and had a light breakfast before attending on each study day. All studies were 
carried out in a quiet, temperature-controlled room, at 22-240C, with the subject 
recumbent throughout, except when voiding urine. 
 
Healthy subjects taking any medications in the previous 2 weeks were excluded from the 
study. Patients continued taking their normal medications up to and including each study 
day with the exception of diuretics, which they omitted that morning.  
 
Estimation of glomerular filtration rate  
GFR was calculated using the Cockcroft & Gault (C&G) equation as an estimate of 
creatinine clearance (Chapter 3): GFR = [140 - age (years)] x weight (kg) x (0.85 if 
female) / serum creatinine.158 GFR was further corrected by body surface area (BSA): 
BSA = [71.84 x weight (kg)0.425 x height (cm)0.725] / 10,000 as defined by Du Bois, et al 
159. The C&G equation was selected to assess renal function in this study because it is 
more accurate than the Modification of Diet in Renal Disease (MDRD) equation when 
used to assess mild renal insufficiency.160, 161  
 
Drug administration 
For systemic intravenous administration, study drugs were infused via an 18 standard 
wire gauge (SWG) cannula sited in an antecubital vein. PAH and Inulin were diluted in 
5% dextrose (Baxter Healthcare Ltd, Thetford, UK) and infused intravenously at a 
constant rate of 2 ml/min. All other drugs were dissolved in physiological saline and 




BQ-123  (Clinalfa AG, Laufelfingen, Switzerland) was used as a selective ETA receptor 
antagonist (Chapter 4). It is a synthetic derivative of BE 18257B, a product of 
Streptomyces misakiensisis and is a cyclic pentapeptide that is highly selective for the 
ETA receptor (IC50: ETA = 7.3 nM, ETB = 18 µM162). Studies with radiolabelled BQ-123 
demonstrate that it binds competitively to the ETA receptor, achieving steady state within 
7 minutes of injection and dissociates with a half-time of 1.4 min163. It is extracted from 
the circulation by the hepatic anion transport system164.  
 
On the basis of previous work from our department53 a dose of 1000 nmol/min BQ-123 
over 15 min was used as that achieving maximal haemodynamic effects. The 
haemodynamic effects of 1000 nmol/min for 15 min are demonstrable for ~2 hours after 
injection and BQ-123 is undetectable in the plasma 150 min following injection. 
 
Sitaxsentan 
Sitaxsentan is an orally active ETA receptor antagonist licensed for the treatment of 
pulmonary arterial hypertension165. It is approximately 6,500-fold more selective as an 
antagonist for the ETA receptor than for the ETB receptor166. In healthy subjects 
sitaxsentan displays linear steady state pharmacokinetics at the 100 mg therapeutic dose 
(with non-linear kinetics at higher doses). It is rapidly absorbed, highly bound to plasma 
proteins (>99.5%), predominantly albumin, and extensively metabolised (CYP2C9 
pathway). However, data suggest that the metabolites of sitaxsentan are unlikely to 
contribute significantly to its therapeutic efficacy. Following oral dosing with 
radiolabelled sitaxsentan at the maximum clinically recommended dose of 100 mg, ~50-
60% of the radioactivity is eliminated via the urine, with only ~1.2% of this due to 
unchanged parent drug. The balance is excreted via the faeces, in which there is no 




Nifedipine 10 mg and nifedipine 30mg LA (Adalat, Bayer) were used as active controls 
in Chapters 4 and 6, respectively, and administered orally. 
 
PAH  
Para-aminohippurate sodium (PAH, Clinalfa AG) was used for the measurement of renal 
plasma flow by standard clearance techniques168 (Chapters 4 and 6). It is an inert and 
non-toxic compound that is both filtered at the glomerulus and actively secreted by the 
proximal tubules, reaching the kidney only via the blood stream. The extraction by the 
kidneys in a single transit is not complete (the full criteria for a marker of renal blood 
flow (RBF) by clearance) but about 80-90%, thus measurements are quoted as 
"effective" renal plasma flow (ERPF). This extraction rate is not affected by BQ-123 in 
man169. 
 
PAH was administered as a bolus loading dose of 0.4 g in 100 ml dextrose 5% over 15 
min, and a maintenance infusion of 6.6 g/L at a rate of 2 ml/min. For subjects with a 
calculated GFR < 50 ml/min, the maintenance dose was reduced by one-third, and by 
two-thirds for those with a GFR < 30 ml/min. 
 
Inulin 
Inutest (Fresenius Pharma, Austria GmbH) was used for the measurement of glomerular 
filtration rate (GFR) by standard clearance techniques168 (Chapters 4 and 6). Inulin is an 
inert and non-toxic complex polyfructose with a molecular weight of 5,200 daltons. It is 
not protein bound, is freely filtered at the glomerulus, is neither secreted not reabsorbed 
within the tubules, nor metabolised within the kidney and hence fulfils the criteria for 
the measurement of GFR by clearance measurements. Its problems with solubility have 
been overcome by the introduction of Sinistrin (Inutest) a related polysaccharide with 
identical clearance. 
 
Inutest was administered as a bolus loading dose of 3.5 g in 100 ml dextrose 5% over 15 
min, and a maintenance infusion of 10 g/L at a rate of 2 ml/min. For subjects with a 
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calculated GFR < 50 ml/min, the maintenance dose was reduced by one-third, and by 
two-thirds for those with a GFR < 30 ml/min. 
 
Blood pressure  
Blood pressure (BP) was recorded in duplicate at each time-point using a validated 
oscillometric sphygmomanometer, the Omron HEM-705CP170. Recordings were 
required to be within 10 mmHg of each other (systolic and diastolic). If not, BP was 
repeated until two consecutive readings did fulfil these criteria. For studies in chapter 7 
ambulatory BP was recorded at the brachial artery using a validated Spacelabs 90217 
ambulatory BP monitor171. Measurements were taken every 30min for 24h and mean 
systolic (SBP), mean arterial pressures (MAP) and diastolic (DBP) calculated. 
 
Arterial stiffness  
Pulse wave velocity (PWV), the gold standard for measurement of arterial stiffness90, 
was measured by the foot-to-foot wave velocity method using the SphygmoCor® system 
(SphygmoCor® Mx, AtCor Medical, Sydney, Australia, version 6.31), in which a high-
fidelity micromanometer (SPC-301, Millar Instruments, Texas, USA) was used to 
determine carotid-femoral PWV.  
 
Pulse wave recordings were made at two sites- the carotid and femoral arteries. At each 
site the foot of the flow wave was identified as the beginning of the sharp systolic 
upstroke. The time delay was measured between the feet of the flow waves at each site 
and designated as the pulse transit time. A tape measure applied to the surface of the 
body was used to find the distance travelled by the pulse wave. ECG gating allows the 
time lapse between the pulse waves at both sites to be calculated from sequential rather 
than simultaneous measurements. PWV was then calculated as the distance: transit time 
ratio and expressed as metres per second. 
 
The SphygmoCor apparatus was also used to measure the radial augmentation index. 
This was derived from averaged radial artery waveforms. Central augmentation index 
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(cAIx), used as a additional measure of arterial stiffness, was calculated from central 
aortic waveforms, which were derived by applying a generalised transfer function to the 
directly measured radial waveforms. 
 
Endothelial function 
Brachial artery flow-mediated dilatation (FMD) was used to assess endothelium-
dependent vasomotor function172. With individuals in a supine position and their arms 
out-stretched perpendicular to the body, the brachial artery was imaged longitudinally 
with ultrasound (Acuson XP 128, Siemen plc, Bracknell, UK) 5 cm above the 
antecubital fossa using a linear array transducer with an imaging frequency of 11 MHz. 
Baseline diameter was recorded for 1 minute. To create a flow stimulus in the brachial 
artery, a BP cuff, which was placed around the upper forearm, was inflated to 50 mmHg 
above SBP in order to occlude blood flow into the forearm for 5 minutes. Following 
deflation of the cuff the artery was scanned for a further 5 minutes. We did not use 
glyceryl trinitrate as a measure of endothelium-independent vasomotor function to avoid 
interference with responses to study drugs. FMD was quantified both as the peak change 
from baseline and as the area under the curve of the change from baseline in brachial 
artery diameter after 5 min of forearm ischaemia. 
 
Cardiac output and heart rate 
Cardiac output (CO, L/min) and heart rate (HR, bpm) were recorded using a well 
validated non-invasive bioimpedance technique (NCCOM3; BoMed Medical 
Manufacturer Ltd, Irvine, California, USA)173, 174. This non-invasive technique measures 
CO by transthoracic bioimpedance. A constant sinusoidal current is applied through dual 
electrodes situated at the root of the neck bilaterally and to the lateral aspect of the trunk 
at the level of the xiphisternum. These electrodes then detect changes in bioimpedance 
related to the cardiac cycle and blood flow. CO is estimated from the measures of 
bioimpedance by the Sramek-Bernstein formula, adapted from the original formula of 
Kubicek174. HR is counted directly from detection of the cardiac electrical cycle. Each 
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reading is the average of 15 consecutive beats. Four such readings were recorded for 
each measurement of CI and HR.  
 
Clearance Studies 
ERPF and GFR were measured by standard clearance techniques168 (Chapters 4 and 6). 
On each study day, an 18 SWG cannulae was sited in an antecubital vein in each arm. 
Diuresis was induced by 500 ml 5% dextrose over 30 min through the left arm cannula. 
After 15 min, the loading doses of PAH & inutest were administered through the same 
cannula. Thereafter, maintenance infusions of PAH and inutest, and 5% dextrose at 180 
ml/hr continued throughout the study. Urine was collected by spontaneous voiding every 
60 min. A two hour period was allowed for water, inutest and PAH equilibration before 
baseline measurements were made over one 60 min urine collection period. Blood 
pressure, CO and HR were recorded every 15 min. At the mid-point of each 60 min 
collection period, blood was sampled from the right antecubital cannula for PAH  inulin, 
and haematocrit measurements. Following baseline recordings measurements were made 
for a further 4 hours. 
 
Figure 2.1 : A standard clearance study. BL : baseline 
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Assays 
At pre-specified time points, venous blood was collected via an 18 SWG cannula for 
plasma measurements. Blood was collected into plain tubes (Sarstedt) for the 
measurement of serum sodium, and into EDTA tubes (Sarstedt) for all other plasma 
measurements. 20 ml aliquots of urine from each voiding were collected into plain tubes 
for the urinary measurements. At pre-specified time points, 20ml aliquots of urine were 
also collected into plain tubes containing 2.5ml of 50% acetic acid for the measurement 
of urinary ET-1. 
 
Haematocrit (Hct) was measured on whole blood. All other blood samples were 
centrifuged immediately at 1000 g at 40C for 20 min, and plasma and urine stored in 
plain tubes at –800C until assay. 
 
Plasma and urinary inulin 
Inulin was determined by spectrophotometry after hydrolysis to fructose. Plasma 
samples were deproteinised with equal volumes of 6% perchloric acid and, after 
centrifugation at 1000 g for 10 min, supernatant was decanted. Urine was diluted 1/20 
with 3% perchloric acid. Resorcinol (1.5 g dissolved in 1 l of ethanol) and HCl/FeCl3 
solution (7.5 mg FeCl3 dissolved in 1 l of molar hydrochloric acid) were added in a 6:6:1 
ratio to the plasma/urine. The samples were then vortexed and incubated at 80oC for 40 
min. Inulin concentrations were then determined against standard curves by absorption 
spectrophotometry at 480 nm. 
 
Plasma and urinary PAH 
PAH was determined by high performance liquid chromatography (HPLC) with 
fluorescence detection. Plasma samples were deproteinised with equal volumes of 6% 
perchloric acid and, after centrifugation at 1000 g for 10 min, supernatant was diluted by 
1/40 with deionised water. Urine samples were diluted 1/4000. Dihydroxybenzylamine 
hydrobromide (DHBA) was used as an internal standard. Samples were injected into the 
HPLC column. The HPLC system consisted of a Waters 510 HPLC pump, WISP 
(Waters Intelligent Sample Processor) and Spherisorb S5 ODS column (Waters Ltd, 
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Watford, Herts. UK) with detection by an LS-5 fluorometric detector (Perkin-Elmer Ltd, 
Beaconsfield, Bucks, UK), with excitation and emission wavelengths of 280 nm and 360 
nm, respectively. The mobile phase consisted of 0.1 molar citrate acetate buffer 
containing 100 mg/L octane sulphonic acid. 
 
Haematocrit 
Hct was measured using a Coulter counter. 
 
Plasma and urine ET-1 
After extraction175, ET-1 was determined by radioimmunoassay176. The mean recovery of 
ET-1, from extraction to assay, was >90% for both plasma and urine. The intra- and 
inter-assay variations were 6.3% and 7.2%, respectively. The cross-reactivity of the 
antibody was 100% with ET-1, 7% for both ET-2 and ET-3, and 10% with big ET-1. 
 
Plasma and urinary sodium 




Urine protein was measured using a colorimetric method with pyrogallol red177.  
 
Sitaxsentan 
Samples for assessment of plasma sitaxsentan were collected into EDTA tubes and stored in 
wet ice. They were centrifuged for 20 minutes at 2,200 g at 4ºC within 30 minutes of 
collection. Plasma concentrations of sitaxsentan were measured using a validated 
LC/MS/MS method (inter- and intra-day assay variability +/- 15%) by MDS Pharma 
Services. In brief, this involved spiking plasma samples with a 13C415N isotopically labeled 
internal standard and precipitating the protein with acetonitrile. The supernatant was 
transferred to clean culture tubes and the samples evaporated to dryness and reconstituted in 
acetonitrile/formic acid. The reconstituted extract was then injected into a HPLC system 
coupled to a MS/MS detector and the signal from the detector then back calculated to a 
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calibration curve to achieve a concentration value. The lower limit of quantitation for 
sitaxsentan was 0.005 µg/mL. The percent unbound sitaxsentan (FU) in each sample was 
calculated according to FU = 100% x (CU/CT) where CU and CT represent the unbound and 
total concentrations, respectively. 
 
Systemic and Renal Data 
Data were stored and analysed using the Microsoft Excel data analysis package (Excel 
5.0, Microsoft Ltd). BP at each time point was calculated as the mean of 2 recordings 
and represented as mean arterial pressure (MAP). Biompedance data at each time point 
were calculated as the mean of four recordings, each the average of 15 consecutive heart 
beats. Data were corrected using body surface area to give cardiac index (CI) for direct 
comparison of subjects, and systemic vascular resistance index (SVRI) derived from BP 
and CI data (Table 2.1).  
 
GFR and ERPF were calculated from inulin and PAH clearances, respectively. Effective 
renal blood flow (ERBF), effective renal vascular resistance (ERVR) and effective 
filtration fraction (EFF) were derived from these indices (Table 2.1). Urinary sodium 
excretion and fractional excretion were calculated from plasma and urinary sodium and 
inulin concentration and urinary flow rates. 
  
 47 








Mean Arterial Pressure 
(MAP) 
 
DBP + (SBP-DBP) 




Systemic Vascular Resistance Index 
(SVRI) 
MAP x 80 
CI 
dyne.s /m2/cm5. 
Glomerular Filtration Rate 
(GFR) 
uIn x UFR 
pIn    
ml/min 
Effective Renal Plasma Flow 
(ERPF) 
uPAH x UFR 
pPAH      
ml/min 










Effective Filtration Fraction 
(EFF) 
GFR  x 100 
ERPF  
% 
Urinary Flow Rate 
(UFR) 
Urinary volume 
Time of collection 
ml/min 
Urinary Sodium Excretion 
(UNaV) 
uNa x UFR µmol/min 
Fractional Excretion of Sodium 
(FeNa) 
uNa x pIn 
pNa    uin 
 
   
 
DBP - diastolic blood pressure, SBP - systolic blood pressure,  u - urine, p - plasma, In - Inulin, PAH - 




Urinary endothelin-1 as a marker of chronic 




Background: Chronic inflammation contributes to the development and progression of 
CKD. Identifying renal inflammation early is important. There are currently no specific 
markers of renal inflammation. ET-1 is pro-inflammatory and implicated in the 
pathogenesis of CKD. Thus, we investigated the impact of progressive renal dysfunction 
and renal inflammation on plasma and urinary ET-1 concentrations.  
 
Methods: In a prospective study, plasma and urinary ET-1 were measured in 115 
subjects with CKD stages 1 to 5 and 27 age- and blood pressure-matched non-CKD 
controls, and fractional excretion of ET-1 (FeET-1) calculated. FeET-1, serum C-
reactive protein (CRP), urinary ET-1:creatinine ratio, and urinary albumin:creatinine 
ratio were also measured in 29 healthy volunteers (HV), 85 subjects with different 
degrees of inflammatory renal disease but normal renal function, and in 10 subjects with 
rheumatoid arthritis without renal involvement (RA). In subjects with nephritis 
associated with systemic lupus erythematosus (SLE) measurements were before and 
after 6 months of treatment. 
 
Results: In subjects with CKD, plasma ET-1 increased linearly as renal function 
declined, whereas FeET-1 rose exponentially. In subjects with normal renal function, 
FeET-1 and urinary ET-1:creatinine ratio were higher in SLE subjects than in other 
groups (7.7 ± 2.7%, 4.7 ± 2.1 pg/µmol, both p < 0.001), and correlated with CRP. 
Notably, they were also significantly higher than in RA subjects (both p < 0.01) with 
similar CRP concentrations. In SLE patients, following treatment, FeET-1 fell to 3.6 ± 
1.4% (p < 0.01). 
 
Conclusions: Renal ET-1 production increases as renal function declines. In subjects 
with SLE, urinary ET-1 may be a useful measure of renal inflammatory disease activity 
whilst measured renal function is still normal. 
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Introduction 
Chronic inflammation is a major contributor to the development and progression of 
CKD178. Current treatments for inflammatory CKD include immunosuppressive therapy, 
which is often associated with significant side effects179. Despite this, however, some 
patients develop progressive renal injury resulting in end-stage renal disease. Also, those 
who respond to treatment remain at risk of further disease relapses. Identifying renal 
inflammatory disease early and assessing its response to treatment remain important 
clinical challenges. Measurement of renal function, using serum creatinine for example, 
is often inadequate because substantial renal tissue damage can occur before function is 
impaired to a detectable extent180. However, serial renal biopsies are not appropriate in 
clinical practice. Current disease markers include serum C-reactive protein (CRP) and 
proteinuria. However, these lack both sensitivity and specificity for renal inflammation. 
There are currently no easily assessable clinical biomarkers specific to renal 
inflammation. Such markers would not only allow early implementation of appropriate 
treatments, with the hope of preventing disease progression, but also help identify future 
disease relapses. 
 
Endothelin-1 (ET-1) is implicated in the development and progression of CKD181, and is 
produced both within the vasculature and the kidney181. Although plasma ET-1 levels are 
not a reliable measure of vascular ET-1 production, owing to its predominantly 
abluminal release16, urinary ET-1 excretion is independent of plasma ET-1 
concentrations 182, 183 and is well-correlated with renal ET-1 production25, 28.  
 
A few small studies have shown a rise in plasma72 and urine184 ET-1 in severe CKD, and 
our group has previously demonstrated increases in plasma and urinary ET-1 
concentrations in 8 subjects with non-inflammatory renal disease, across a range of 
glomerular filtration rates (GFR)183. However, there are no data on how renal 
inflammation may alter these profiles and hence on the utility of urinary ET-1 as a 
potential biomarker of renal inflammation. 
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Thus, we hypothesised that, as a result of reduced clearance and increased renal 
production respectively, plasma and urinary ET-1 concentrations would increase as GFR 
declined, and that in subjects with varying degrees of inflammatory CKD, but normal 
renal function, urinary ET-1 would act as a surrogate measure of the underlying renal 
inflammation. Our main groups of interest were thin basement membrane disease 
(TBM), immunoglobulin A nephropathy (IgAN) and systemic lupus erythematosus 
(SLE) with nephritis as examples of non-inflammatory, mild and more florid 
inflammatory renal diseases respectively.  
 
Methods 
This was a prospective and cross-sectional study. 
 
Subjects 
For Study 1, the inclusion criteria were: male or female CKD patients, 18 – 65 years old 
with a BP ≤ 160/100 mmHg. We excluded patients with a renal transplant, those 
requiring dialysis, and patients with a history of established cardiovascular disease, 
peripheral vascular disease, diabetes mellitus, respiratory disease, and neurological 
disease. Additionally, a systemic inflammatory disorder such as SLE or vasculitis was a 
specific exclusion criterion. Age- and BP-matched non-CKD subjects were recruited 
from the community.  
 
For Study 2, we included male and female subjects aged 18-70, with haematuria and/or 
proteinuria of presumed glomerular origin. All subjects had a serum creatinine and GFR 
in the normal range and no history of hypertension. We excluded subjects with any 
significant co-morbidity. Rheumatoid arthritis (RA) subjects (as a control group for the 
SLE cohort) were recruited from the Rheumatology outpatient clinic at the Western 
General Hospital, Edinburgh. 
 
Study protocol 
Following a brief medical enquiry to confirm suitability for the study, body weight and 
height of the participants were recorded. After 30 min of supine rest, BP and heart rate 
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were recorded. Following this, blood was taken for analysis (serum creatinine, 
cholesterol, CRP and plasma ET-1), and urine collected (creatinine, albumin:creatinine 
ratio and ET-1), and tested for presence of blood and/or protein. Glomerular filtration 
rate was assessed using the Cockcroft & Gault equation (Chapter 2). 
 
Data and statistical analysis 
Data were stored and analysed in Microsoft Excel (version 11.3.7, Microsoft Ltd). 
Fractional excretion of ET-1 (FeET-1) was calculated by [(urine ET-1/plasma ET-1 x 
plasma creatinine/urine creatinine) x 100]%. Descriptive data are given as means ± SD. 
The D’Agostino and Pearson omnibus test was used to evaluate the distribution 
characteristic of the data. Means were compared by one-way Analysis of Variance 
(ANOVA), Kruskal-Wallis test, unpaired Student’s t-test, and Mann-Whitney test where 
appropriate. Correlation coefficients were calculated using the Pearson method. To 
measure the sensitivity and specificity for FeET-1 at different values, a receiver-operator 
curve (ROC) curve was generated using subjects with IgAN and microhaematuria as 
controls. The area under curve was calculated to ascertain the quality of FeET-1 as a 
biomarker. An area of 0.5 is no better than expected by chance, whereas a value of 1.0 




142 subjects were enrolled into this study (115 CKD and 27 matched non-CKD 
subjects). CKD diagnoses were autosomal dominant polycystic kidney disease (n = 26), 
IgAN (n = 24), reflux nephropathy (n = 11), chronic glomerulonephritis (n = 10), non-
inflammatory glomerular disease (n = 8), obstructive nephropathy (n = 5), TBM (n = 2), 
cystinuria (n = 2), Alport’s disease (n = 1), and medullary cystic kidney disease (n = 1). 
25 CKD subjects had no known cause for their renal disease. GFR ranged from 8 to 154 
ml/min/1.73m2. Baseline characteristics of all study subjects are shown in Table 3.1.  
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There was a negative linear correlation between GFR and plasma ET-1 (Table 3.2 and 
Figure 3.1a, r2 = 0.22, p < 0.001). FeET-1 increased exponentially as GFR declined 
(Table 3.2 and Figure 3.1b, r2 = 0.47, p < 0.001). Whereas plasma ET-1 did not correlate 
with BP, there was a positive correlation between BP and FeET-1 (r2 = 0.04, p < 0.05). 
There was no relationship between GFR and serum CRP, consistent with our subjects 
comprising of a non-inflammatory cohort of CKD patients. 
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Table 3.1: Demographic data for non-CKD and CKD subjects in Study 1. BMI: body 
mass index, FeET-1: fractional excretion of ET-1, SBP: systolic blood pressure, DBP: 
diastolic blood pressure, eGFR: estimated glomerular filtration rate, CRP: C-reactive 




Non-CKD subjects  










48 ± 9 (32 – 64) 47 ± 10 (23 – 65) ns 
Sex, M/F 13/14 77/38 - 
 




110 ± 17 (83 - 152) 119 ± 15 (85 – 159) ns 
DBP, mmHg 
 
70 ± 10 (54 – 90) 74 ± 9 (52 – 96) ns 
Creatinine, µmol/l 
 
78 ± 13 (55 – 98) 194 ± 164 (55 – 825) p < 0.001 
eGFR ml/min/1.73m2 94 ± 18 (68 – 131) 63 ± 35 (8 – 154) p < 0.001 
 
Cholesterol , mg/dl 
 
5.0 ± 0.8 (3.4 – 6.6) 4.6 ± 0.9 (3.0 – 8.2) p < 0.05 
CRP, mg/l 2 ± 3 (0 -12) 4 ± 4 (0 – 15) p < 0.05 
Plasma ET-1, pg/ml 
 
4.6 ± 1.0 (2.8 – 7.5) 
 
5.5 ± 1.1 (3.4 – 9.8) p < 0.001 





0.5 ± 0.8 (0 – 3.3) 
 
48.6 ± (0 – 428) p < 0.001 
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Table 3.2: Plasma ET-1 (pg/ml) and fractional urinary excretion of ET-1 (FeET-1, %) 
for subjects in Study 1 at different estimated glomerular filtration rates (eGFR). Values 
























6.1 ± 1.2 
(4.3 – 8.7) 
 
5.8 ± 1.2 
(4.0 – 9.8) 
 
4.9 ± 1.0 









6.8 ± 3.5 
(1.0 – 14.7) 
 
3.2 ± 2.7 
(6.0 – 12.7) 
 
1.1 ± 0.7 





Figure 3.1: Scatter plots for estimated glomerular filtration rate (eGFR, ml/min/1.73m2) 
and (A) plasma ET-1 (pg/ml), r2 = 0.22, p < 0.001, and (B) fractional urinary excretion 






























r2 = 0.22, p < 0.001 





114 subjects took part in Study 2: healthy volunteers (HV, n = 29), TBM (n = 8), IgAN 
(n = 22), microscopic haematuria of presumed glomerular origin (MH, n = 35), SLE 
with nephritis (n = 10), and rheumatoid arthritis without renal involvement (RA, n = 10). 
All subjects with TBM, IgAN and lupus nephritis had biopsy-proven renal diagnoses. Of 
those with SLE, 4 had type IV lupus nephritis on renal biopsy, 2 type V, and 4 both 
types IV and V185. These subjects were studied before, and 6 months after, the start of 
treatment. This comprised of oral prednisolone for all 10 subjects, with 6 additionally 
receiving mycophenolate mofetil as a steroid-sparing agent, and the remaining 4 subjects 
receiving cyclophosphamide. All subjects in Study 2 had normal renal function with 
GFRs ranging from 61 to 153 ml/min/1.73m2. A cohort of subjects with rheumatoid 
arthritis (RA) were included as a control group for those with lupus nephritis as having a 
similar degree of systemic inflammation, as measured by serum CRP, but no evidence of 
renal disease as shown by a clear urinalysis and GFR >60 ml/min/1.73m2. Subject 
characteristics are shown in Table 3.3.  
 
Table 3.3 (overleaf): Study 2 subjects: healthy volunteers (HV), and subjects with thin 
basement membrane disease (TBM), immunoglobulin A nephropathy (IgAN), 
microhaematuria of presumed glomerular origin (MH), systemic lupus erythematosus 
with nephritis (SLE) and rheumatoid arthritis (RA). BMI: body mass index, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, eGFR: estimated glomerular 
filtration rate, CRP: C-reactive protein, ACR: albumin:creatinine ratio. Values are mean 
± SD (range). For CRP ***p < 0.001 for SLE vs. all renal groups. For ACR *p < 0.05, 











(n = 8) 
 
IgAN 
(n = 22) 
 
MH 
(n = 35) 
 
SLE 
(n = 10) 
 
RA 




46 ± 10 
(32 – 64) 
42 ± 11 
(26 – 60) 
41 ± 11 
(24 – 59) 
45 ± 13 
(22 – 64) 
40 ± 14 
(26 – 60) 
 
44 ± 8 












25 ± 4  
(18 – 34) 
 
26 ± 5 
(19 – 31) 
 
27 ± 4 
(22 – 36) 
 
28 ± 5 
(21 – 39) 
 
26 ± 5 
(19 – 29) 
25 ± 4  





119 ± 18  
(84 - 152) 
 
115 ± 10 
(101 – 124) 
 
117 ± 9 
(106 – 132) 
 
121 ± 14 
(8 – 156) 
 
124 ± 17 
(96 – 151) 
131 ± 13  





73 ± 10 
(59 – 93) 
 
76 ± 5 
(67 – 81) 
 
74 ± 8 
(62 – 96) 
 
78 ± 11 
(57 – 111) 
 
77 ± 11 
(63 – 87) 
76 ± 8 





77 ± 12  
(55 – 93) 
 
73 ± 10 
(60 – 87) 
 
92 ± 23 
(49 – 115) 
 
81 ± 16 
(49 – 118) 
 
83 – 21 
(59 – 126) 
81 ± 9  





94 ± 16 
(62 – 130) 
 
102 ± 13 
(74 – 115) 
 
97 ± 26 
(61 – 153) 
 
97 ± 25 
(68 – 130) 
 
97 ± 27 
(61 – 142) 
89 ± 19 





5.0 ± 0.9  
(3.8 – 7.3) 
 
5.3 ± 1.1 
(3.3 – 5.9) 
 
4.6 ± 0.7 
(3.6 – 5.9) 
 
5.2 ± 1.1 
(3.2 – 8.8) 
 
4.9 ± 0.8 
(3.7 – 6.1) 
5.0 ± 1.1  





1 ± 2 
(0 – 10) 
 
1 ± 2 
(0 – 6) 
 
2 ± 2 
(0 – 10) 
 
3 ± 4 
(0 - 14) 
 
63 ± 15*** 
(45 – 87) 
61 ± 16 





0.6 ± 1.0*** 
(0 – 3.6) 
 
1.6 ± 2.3* 
(0 – 6.6) 
 
26.9 ± 46.0 
(0 – 173.5) 
 
2.3 ± 3.5** 
(0 – 15.2) 
 
27.8 ± 27.0 
(4.3 – 89.3) 
1.1 ± 0.8* 
(0 – 2.6) 
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Table 3.4: Legend as for Table 3.3. FeET-1: fractional excretion of ET-1. *p < 0.05 for 










(n = 8) 
 
IgAN 
(n = 22) 
 
MH 
(n = 35) 
 
SLE 
(n = 10) 
 
RA 




5.3 ± 1.8 
(2.8 – 11.0) 
4.4 ± 0.8 
(3.3 – 6.0) 
5.1 ± 1.0 
(4.0 – 6.9) 
4.5 ± 0.7 
(3.6 – 13.2) 
4.7 ± 0.9 
(3.3 – 6.0) 
 
4.6 ± 0.9 




1.3 ± 0.9 
(0.3 – 4.4) 
 
1.6 ± 0.8* 
(1.0 – 3.1) 
 
1.1 ± 0.4 
(0.2 – 1.6) 
1.4 ± 0.7 
(0.2 – 3.8) 
7.7 ± 2.7*** 
(4.8 – 12.6) 
3.7 ± 2.1 




0.8 ± 0.5 
(0.1 – 2.6) 
 
1.0 ± 0.5* 
(0.5 – 2.2) 
0.9 ± 0.5 
(1.4 – 8.4) 
0.9 ± 0.5 
(1.4 – 8.4) 
4.7 ± 2.1*** 
(1.4 – 8.4) 
2.1 ± 1.3 
(0.9 – 4.7) 
 
All groups of subjects had similar plasma ET-1 concentrations (Table 3.4 & Figure 
3.2a). However, both FeET-1 and urinary ET-1:creatinine ratio were significantly higher 
in lupus nephritis subjects compared to HV and all other renal groups (Tables 3.3, 3.4 & 
Figure 3.2c & 3.2d). Both FeET-1 and urinary ET-1:creatinine ratio were similar 
between HV, TBM, IgAN and MH.  
 
CRP concentrations followed a similar pattern (Table 3.3 & Figure 3.2b, SLE: 63 ± 15 
mg/l, p < 0.001 vs. HV and other renal subjects). Despite similar CRP concentrations to 
subjects with RA (Table 3.3 & Figure 3.2b, RA: 61 ± 16 mg/l), subjects with lupus 
nephritis had a significantly higher FeET-1 and urinary ET-1:creatinine ratio (Table 3.4 
& Figure 3.2c & 3.2d). RA subjects also had higher urinary ET-1:creatinine ratio (p < 
0.05), and FeET-1 (p < 0.01) than HV and subjects with MH and IgAN. There was no 






















Figure 3.2: (A) Plasma ET-1 (pg/ml), (B) serum C-reactive protein (CRP, mg/l) (C) 
FeET-1 (%), and (D) urinary ET-1: creatinine (pg/µmol). For all panels horizontal black 
bars show mean value. Panel (B): ***p < 0.001 for SLE vs. all groups except RA, for 
which p = ns. Panels (C) and (D): *p < 0.05 for SLE vs. TBM, ***p < 0.001 for SLE vs. 




















































For FeET-1, the area under the ROC was 1.0 (curve not shown). Table 3.5 lists the 
derived sensitivities and specificities at different cutoff values for FeET-1. A value 
above 2.7% in renal patients yielded good sensitivity and specificity for the detection of 
SLE. 
 















































0.92 – 1.00 
 
 
For subjects with SLE and nephritis, FeET-1 fell significantly following treatment 
(Figure 3, 7.7 ± 2.7 vs. 3.6 ± 1.4%, p < 0.01). Effects of treatment on other disease 
markers is shown in Table 3.6. 
 
Figure 3.3 (overleaf): (A) FeET-1 (%) and (B) albumin:creatinine ratio (ACR) in 
patients with systemic lupus erythematosus with nephritis pre- and post-treatment. *p < 




































































   










Table 3.6: C-reactive protein (CRP), albumin:creatinine ratio (ACR), double-stranded 
DNA (dsDNA) and complement levels in subjects with lupus nephritis pre- and post-
















63 ± 15 
 
 
5 ± 3 
 
p < 0.001 
ACR (mg/mmol) 
 
27.8 ± 27.0 
 
19.1 ± 18.6 p < 0.05 
dsDNA, 
(0 – 15, iu/ml) 
 
102 ± 86 
 
92 ± 93 p < 0.05 
Complement (g/l) 
 
C3 (0.73 – 1.4) 




0.73 ± 0.20 
0.13 ± 0.06 
 
 
0.78 ± 0.11 
0.17 ± 0.03 
 
 
p = ns 





Consistent with our previous findings in a limited number of subjects (8 CKD and 8 
healthy controls)183, we have now demonstrated in a large cohort of subjects that plasma 
ET-1 increases linearly as GFR declines, whereas FeET-1 shows an exponential rise. We 
have also shown for the first time that urinary ET-1 concentrations are raised in patients 
with systemic inflammatory disease and active renal involvement (but not systemic 
inflammatory disease without renal involvement), even when GFR is normal, whilst 
there is little impact of inflammation on plasma ET-1. Finally, in inflammatory renal 
disease urinary ET-1 concentrations fall following successful disease treatment. Thus, 
urinary ET-1 may be a useful marker of renal inflammation in the early stages of 
inflammatory renal disease, before renal function is affected, and may help direct 
treatment in these conditions. 
 
Previous studies have shown increased plasma ET-1 concentrations in pre-dialysis72, 186 
and dialysis-requiring72, 187 CKD patients. Our results are in keeping with these studies. 
However, we have also demonstrated that plasma ET-1 increases linearly as renal 
function declines, across a wide range of GFRs and in a relatively homogeneous, non-
inflammatory CKD population. This is likely to be largely due to reduced renal filtration 
of ET-1 and thus renal clearance from the circulation. Importantly, we have also shown 
an exponential rise in FeET-1 as GFR declines. It is well established that a number of 
renal cell types are able to synthesise ET-16, 26, 181, and that ET-1 is an important regulator 
of renal function in CKD53, 181. It has been shown in animal models that plasma ET-1 
does not account for urinary ET-128 and that renal cortical interstitial ET-1 levels 
correlate with urinary ET-1 excretion25. We have also previously demonstrated that 
plasma and urinary ET-1 change independently of one another in CKD183. These data 
support the view that urinary ET-1 concentrations reflect renal ET-1 production in CKD. 




The results of our study suggest that urinary ET-1 is a useful marker of active renal 
inflammation in patients with lupus nephritis and normal renal function. Urinary ET-1 
levels in subjects with TBM disease, a non-inflammatory condition, and in those with 
IgAN nephropathy, associated with mild renal inflammation, were no different to those 
in healthy volunteers. These findings are consistent with renal ET-1 production being 
driven by more florid inflammatory renal disease as is seen in lupus nephritis. In this 
study we used spot urine samples, as are collected routinely in the clinic, rather than 
timed urine collections making the data more widely clinically applicable. Whilst a 
urinary biomarker of disease activity would be ideal, being non-invasive and readily 
available, our results show an overlap in urinary ET:creatinine ratios between different 
renal groups. However, our sample size is small and it will be important to see if the 
same holds true in a larger cohort of subjects. Interestingly, the lack of overlap between 
FeET-1 levels in subjects with active lupus nephritis and levels in healthy volunteers and 
those with other renal diagnoses does support its use as a discriminatory test in the 
clinical management of lupus nephritis. Consistent with this is the area under the ROC 
of 1.0. Although calculation of FeET-1 requires both a blood and urine sample, it should 
still be feasible in most renal clinics. This would be of particular help in the assessment 
of renal disease activity because involvement of different organs in SLE is variable. 
Thus, in the group of patients who present to the renal clinic with an active urinary 
sediment but in the presence of normal renal function an elevated urinary ET-1 level 
may help identify those who have more active inflammatory renal disease, such as lupus 
nephritis.  
 
FeET-1 and CRP were both significantly elevated in subjects with lupus nephritis 
compared to healthy volunteers and subjects with other renal diagnoses. Thus, one may 
argue that it is the systemic inflammation in lupus nephritis that is driving the increase in 
renal ET-1 production. However, when we compared urinary ET-1 concentrations in 
subjects with newly diagnosed and untreated rheumatoid arthritis, with a similar degree 
of systemic inflammation as reflected by a similar CRP, but with no evidence of renal 
involvement, FeET-1 was significantly higher in those with lupus nephritis. These data 
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suggest that the increase in urinary ET-1 in lupus nephritis is predominantly in response 
to the renal inflammation. As the current study had limited numbers we are unable to 
comment on the relationship between histological class of lupus nephritis and renal ET-1 
production, but this is an area of ongoing study. Interestingly, although subjects with 
rheumatoid arthritis had a lower FeET-1 than those with lupus nephritis, they had a 
greater FeET-1 than healthy volunteers and those with other renal diagnoses suggesting 
that systemic inflammation may, in part, contribute to renal ET-1 production. Indeed, 
previous studies suggest that inflammatory mediators stimulate ET-1 production188, 189. 
 
The current clinical study was designed to look at a pre-selected group of patients: those 
referred to the renal clinic on the basis of an abnormal urinalysis (haematuria +/- 
proteinuria) but in the presence of normal renal function. Our active control group 
ideally needed to comprise of subjects with a similar degree of systemic inflammation to 
those with lupus nephritis but with no evidence of renal disease. We chose patients with 
rheumatoid arthritis as they commonly present to the rheumatology clinic. They often 
have evidence of systemic inflammation but it is uncommon for the kidney to be 
involved190, especially at the outset of disease. Although one may argue subjects with 
untreated SLE without nephritis may have been a better choice of control, these patients 
have variable CRP levels191, 192 despite other evidence of systemic inflammation193, 194, 
and their degree of inflammation is considerably less when not associated with nephritis. 
Clearly, comparing urinary ET-1:creatinine ratio and FeET-1 in those with SLE in the 
presence and absence of nephritis would be of some interest and an area of future study.   
 
One problem in the management of lupus nephritis is assessing the response to 
immunosuppressive treatment as well as the early detection of relapse. A rising serum 
creatinine may be due to active disease or progressive renal scarring. However, serial 
renal biopsies are not without risk, making a simpler test desirable. The data from the 
current study show a significant fall in FeET-1 in subjects with lupus nephritis following 
successful treatment. At 6 months, all subjects were in clinical disease remission as 
defined by an improvement in symptoms and a fall in CRP. Importantly, all subjects 
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showed a fall in FeET-1. By contrast, some (6 of 10), but not all, showed a resolution of 
their microscopic haematuria, and/or reduction in proteinuria (7 of 10). Other 
immunological markers of disease activity (double-stranded DNA and complement 
levels) also showed variable changes. Thus, these data suggest that a fall in urinary ET-1 
may be a useful additional marker of response to therapy. Whether monitoring urinary 
ET-1 levels may be useful in detecting patients who do not respond to therapy remains 
unclear. As a limitation, we recognise that the heterogeneity in treatment given may 
impact on the data and this should be studied further. Furthermore, none of the 10 
patients relapsed within the 6-month period and it remains speculative whether urinary 
ET-1 levels would rise before clinical relapse and this should also be the focus of larger 
studies. 
 
It is important to consider whether renal impairment or significant proteinuria would 
affect the utility of urinary ET-1 as a biomarker of renal inflammation. The results of 
Study 1 demonstrate that in patients with non-inflammatory CKD FeET-1 only begins to 
increase at a GFR of ~60 ml/min. All of the subjects with lupus nephritis in Study 2 had 
better renal function than this. It would be of great interest to see whether FeET-1 levels 
were higher in subjects with severe enough inflammatory renal disease to cause 
deterioration in GFR (<60 ml/min), such as in those with small vessel vasculitis, than in 
subjects with similar GFRs but non-inflammatory CKD, and whether levels remained 
higher in those without active inflammation. With regard to proteinuria, our data show 
no relationship between urinary ET-1 concentrations and degree of proteinuria. This is in 
contrast to others who have shown both microalbuminuria195 and nephrotic range 
proteinuria141 associated with urinary ET-1 albeit in different cohorts of patients. 
Certainly, both in vitro126 and in vivo127 experiments have shown that proteinuria may 
stimulate renal ET-1 production and this was associated with damage to the podocyte. 
All our subjects had low-grade proteinuria and whether higher degrees would relate to 
urinary ET-1 and whether alterations in podocyte function contribute to the development 
of lupus nephritis remains unclear and should be another area for further study.  
 
 68 
Our data add to the existing and expanding literature on urinary biomarkers of 
inflammatory renal disease, in particular relating to lupus nephritis196. In a recent study 
by Pitashny et al197, urinary lipocalin-2 levels were found to be higher in subjects with 
SLE in the presence of nephritis than in its absence. However, there was significant 
overlap in lipocalin-2 levels between the two groups, the population studied included a 
majority of Hispanics and African Americans, and the response to disease treatment was 
not assessed.  
 
In conclusion, in the current study we have found that urinary ET-1 may act as a useful 
marker of active renal inflammation in lupus nephritis and provide additional clinically 
relevant information about disease activity to that given by established markers. Further 
study is needed to investigate whether rising urinary ET-1 concentrations are useful in 
identifying patients who do not respond to therapy or predicting a relapse, and whether 
different therapies may have variable effects on urinary ET-1. Furthermore, studying 
patients with other inflammatory renal diseases such as those with small vessel 
vasculitis, would be of great interest. ET-1 is pro-inflammatory and its upregulation in 
CKD may contribute to disease progression181. Thus, antagonising the effects of ET-1 
may offer therapeutic benefits in patients with CKD, and this is supported by pre-clinical 
and clinical data53, 198. 
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 Chapter 4 
 
Acute endothelin-A receptor antagonism reduces 
blood pressure, arterial stiffness and proteinuria 




Background: ET-1 is implicated in the development and progression of CKD. We 
therefore studied the effects of selective ETA receptor antagonism with BQ-123 on BP, 
proteinuria and renal haemodynamics, arterial stiffness and endothelial function in 
patients with CKD. 
 
Methods: In a double-blind, randomised crossover study, 22 subjects with proteinuric 
CKD received, on two separate occasions, placebo or BQ-123. 10 of these subjects also 
received nifedipine 10mg as an active control for the antihypertensive effect of BQ-123. 
BP, pulse wave velocity (PWV), flow-mediated dilatation (FMD), renal blood flow 
(RBF) and glomerular filtration rate (GFR) were monitored following drug dosing.  
 
Results: BQ-123 reduced BP (mean arterial pressure: -7±1%, p <0.001 vs placebo), and 
increased RBF (17±4%, p<0.01 vs placebo). GFR did not change. Proteinuria (-26±4%, 
p<0.01 vs placebo) and PWV (-5±1%, p<0.001 vs placebo) fell after BQ-123, but it had 
no acute effect on FMD. Nifedipine matched the BP and RBF changes seen with BQ-
123. Nevertheless, BQ-123 reduced both proteinuria (-38±3 vs 26±11%, p<0.001) and 
PWV (-9±1 vs -3±1%, p<0.001), to a greater extent than nifedipine. 
 
Conclusions: Selective ETA receptor antagonism reduces BP, proteinuria and arterial 
stiffness on top of standard treatment in CKD patients. Furthermore, these studies 
suggest the reduction in proteinuria and arterial stiffness is independent of BP. If 
maintained longer term, the effects of selective ETA receptor antagonism would confer 
both cardiovascular and renal protection in patients with CKD. 
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Introduction 
Chronic kidney disease (CKD) is common199. Hypertension is an independent risk factor 
for CKD progression200, and is a frequent finding in patients with CKD. Its prevalence 
increases as CKD progresses, with over 75% of patients with a glomerular filtration rate 
(GFR) <30ml/min having a blood pressure (BP) >140/90mmHg201. Despite treatment 
with multiple antihypertensive agents the majority of CKD patients fail to reach target 
BP202.  
 
Proteinuria is a common feature of CKD and its presence is independently associated 
with an adverse renal outcome203. Current treatments for proteinuria focus on BP 
reduction119, ideally using angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs)204, both of which are inhibitors of the renin-
angiotensin system and thought to reduce proteinuria to a greater extent than accounted 
for by BP-lowering alone205. Nevertheless, many CKD patients have significant residual 
proteinuria despite optimal treatment206.  
 
CKD is also strongly associated with incident cardiovascular disease (CVD)207. The US 
National Kidney Foundation Task Force on CVD in Chronic Renal Disease recognises 
that patients with CKD should be considered in the ‘highest risk group’ for subsequent 
cardiovascular events208. Hypertension209 and proteinuria210 make an important 
contribution to CVD risk in CKD, as do arterial stiffness87, 89 and endothelial 
dysfunction77. Thus, there remains an unmet need for newer treatments in CKD that will 
not only lower BP and proteinuria beyond the levels achieved with standard therapies, 
but may also have favorable effects on arterial stiffness and endothelial dysfunction and 
so offer longer term cardiovascular and renal protection. 
 
Endothelin-1 (ET-1) is is implicated in both the development and progression of CKD, 
and contributes to CVD181. Our group has previously shown that selective ETA receptor 
antagonism, but not mixed ETA/B antagonism, reduces BP, increases renal blood flow 
and reduces effective filtration fraction in patients with CKD53. ET-1 also contributes to 
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arterial stiffness22 and endothelial dysfunction82, 95 in patients with vascular disease, 
however, there are no studies in renal patients. 
 
Based on our previous work53, we hypothesised that in patients with proteinuric CKD, 
acute selective ETA receptor antagonism would reduce BP and proteinuria, and 
additionally reduce arterial stiffness and improve endothelial dysfunction. As we have 
previously demonstrated a synergism between ACE inhibitors and selective ETA 
receptor antagonism in health211, we expected these effects to be evident on top of 




We enrolled subjects 18-70 years of age with stable CKD stages 1 to 4201 and proteinuria 
(>300 mg/day). Subjects were on treatment with ACE inhibitors and/or ARBs for their 
proteinuria (see Table 4.3). Explicitly, doses of one or both of drugs were titrated to the 
maximum tolerated, dependent on BP, renal function, serum potassium levels and side 
effects. All medications were unchanged over the 3 months preceding the studies. 
 
Patients with significant co-morbidity, including diabetes mellitus, heart or lung disease, 
and peripheral vascular disease were excluded. To enhance homogeneity and avoid other 
influences on vascular reactivity, patients with vasculitis, other systemic inflammatory 




This was a randomised, double-blind, placebo-controlled study with a sub-study using 
an open-label active control arm. The main study looked at the effects of the selective 
ETA receptor antagonist BQ-123 compared to saline placebo. As previous studies with 
BQ-123 have shown a reduction in BP in CKD patients, and as this may contribute to 
changes in arterial stiffness, protein excretion and natriuresis, nifedipine 10mg given 
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orally was used as an active control for this reduction in MAP in those subjects taking 
part in the sub-study.  
 
All subjects attended for 2 visits, receiving placebo and BQ-123 in a randomised order, 
with those taking part in the sub-study (nifedipine 10mg) attending for three randomised 
visits. Since previous studies with the same dose of BQ-123 have demonstrated that 
haemodynamic changes return to baseline after 4 hours,46, 53, 212, and the half-life of 
nifedipine is ~2 hours, each visit was separated by ≥7 days to ensure complete washout 
of the study drugs. On each study day, a clearance study was carried out as previously 
described (Chapter 2).   
 
Statistical analysis 
The number of subjects required to show a significant difference in BP and ERVR was 
based on previous data in CKD patients using the same dose of BQ12353. The co-
primary endpoints were reductions in BP and proteinuria, with the secondary endpoints 
being a reduction in arterial stiffness and improvement in endothelial function. Baseline 
haemodynamic data were calculated as the mean of the 2 time points that immediately 
preceded administration of the study drug. For urine data, only one baseline 
measurement was used immediately prior to drug dosing. Haemodynamic and urine 
results are expressed as mean ± SEM change from baseline for drug and placebo, and 
placebo-corrected change from baseline for sub-study results. Statistical analysis was 
performed on untransformed data. Three comparisons of interest were pre-identified as 
placebo vs. BQ-123, placebo vs. nifedipine, and BQ-123 vs. nifedipine. Responses were 
examined by repeated measures ANOVA, and Bonferroni correction was used to assess 
significance at specific time points. Statistical significance was taken at the 5% level. 
 
Results 
22 patients with stable proteinuric CKD aged 46 ± 3 (29 – 69) years were recruited into 
the studies. All 22 CKD patients completed the placebo and BQ-123 phases of the study 
without adverse events. All subjects had similar baseline urinary protein leak on each 
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study day. Patient diagnoses were IgA nephropathy (n = 9), membranous 
glomerulopathy (n = 5), and focal segmental glomerulosclerosis (n = 8). Subject 
demographics are shown in Table 4.1 with baseline parameters, including renal function 
and proteinuria, shown in Table 4.2. Table 4.3 shows individual subject characteristics. 
 





Main study (n = 22) 
 
 




46 ± 3 (29 – 69) 
 
45 ± 11 (29 – 64) 
 
Body mass index, kg/m2 
 
28 ± 1 (20 – 37) 
 




93 ± 2 (75 - 118) 
 




191 ± 29 (78 – 487) 
 




170 ± 8 (127 – 228) 
 
166 ± 35 (127 – 228) 
 
Urinary sodium excretion, 
mmol/24h 
163 ± 18 (39 – 300) 
 
174 ± 75 (39 - 300) 
 
Urinary protein excretion,  
g/24h 
 
2.7 ± 0.7 (0.4 - 8.7) 
 
2.9 ± 2.8 (0.4 – 8.0) 
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Table 4.2: Baseline data for main study and sub-study. Values are given as mean of 
baseline pre-treatment periods over the 2 or 3 study days ± SEM (range). 
 
  
Main study (n = 22) 
 
 




92 ± 2 (80 – 103) 
 




3360 ± 230 (1800 – 5510) 
 





3.0 ± 0.2 (1.8 – 4.7) 
 
2.9 ± 0.2 (1.8 – 4.4) 
 
Heart rate, bpm 
 
56 ± 2 (38 – 75) 
 




7.5 ± 0.4 (5.5 – 12.2) 
 




4.4 ± 0.6 (0.6 – 12.7) 
 




1810 ± 233 (106 – 4632) 
 




11.5 ± 4.4 (2.0 – 107.8) 
 




43 ± 5 (12 – 99) 
 




197 ± 21 (27 – 392) 
 
193 ± 28 (95 – 392) 
 
Urinary protein excretion, 
µg/min 
 
1570 ± 371 (165 – 8616) 
 
1520 ± 577 (109 – 8616) 
 
Plasma ET-1 pg/ml 
 
5.7 ± 0.3 (3.6 – 10.5) 
 
6.7 ± 0.5 (3.8 – 8.7) 
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Table 4.3: Subject diagnoses and medications. Doses are total per day. IgAN: 
immunoglobulin A nephropathy; FSGS: focal & segmental glomerulosclerosis; 















1 IgAN Ramipril 2.5mg 
 
  
2 Membranous Ramipril 10mg Candesartan 4mg Atorvastatin 20mg 
Furosemide 40mg 
 





4 FSGS Ramipril 10mg Candesartan 4mg Simvastatin 80mg 
Zopiclone 12.5mg 
 
5 IgAN Lisinopril 40mg Candesartan 4mg Atorvastatin 20mg 
 
6 IgAN Ramipril 2.5mg 
 
  
7 IgAN Ramipril 5mg 
 
  





Sodium bicarbonate 3g 
 











10 Membranous Enalapril 40mg Losartan 50mg Amlodipine 5mg 
 





12 IgAN Ramipril 10mg Candesartan 32mg Aspirin 75mg 
Atorvastatin 40mg 
 





14 IgAN Lisinopril 40mg Candesartan 16mg Aspirin 75mg 
Rosuvastatin 40mg 
 
15 FSGS Ramipril 10mg Valsartan 160mg Amlodipine 5mg 
Allopurinol 200mg 
 




17 IgAN Ramipril 10mg 
 
  
18 Membranous Ramipril 10mg  Amlodipine 5mg 
Atenolol 50mg 
 
19 Membranous Lisinopril 40mg  Metoprolol 100mg 
Omeprazole 20mg 
 
20 FSGS Lisinopril 40mg Valsartan 80mg Atorvastatin 20mg 
 




22 FSGS Ramipril 10mg 
 






Systemic haemodynamics (Figure 4.1a & 4.1b) 
Placebo was associated with increases in both MAP (93.1 ± 2.1 vs. 98.8 ± 2.4 mmHg, p 
< 0.001), and SVRI (3360 ± 230 vs. 3670 ± 290 dyne/s/m2/cm5, p < 0.05) from baseline 
to study end. BQ-123 led to reduction in both MAP (-9.2 ± 1.2 mmHg, p < 0.001 vs. 
placebo), and SVRI (-610 ± 100 dyne/s/m2/cm5, p < 0.001 vs. placebo), with the peak 
effects at 75 min following drug administration. There were no significant differences in 
heart rate between placebo and BQ-123 throughout the time course of the study. 
 
Arterial stiffness and endothelial function (Figure 4.1c) 
Whereas PWV increased following placebo (7.5 ± 0.4 vs. 7.8 ± 0.4 m/s, p < 0.001), BQ-
123 was associated with a significant fall in PWV (-0.8 ± 0.1 m/s, p < 0.001 vs. 
placebo). With regards to endothelial function, there were no differences in FMD 
response between BQ-123 (4.4 ± 0.5 vs. 5.5 ± 0.8%, p = 0.056), and placebo (4.4 ± 0.6 
vs. 5.1 ± 0.7%, p = 0.082).  
 
Renal haemodynamics (Figure 4.2a & 4.2b) 
Administration of placebo was associated with a gradual reduction in ERBF (1810 ± 233 
vs. 1454 ± 181 ml/min, p < 0.001), and increase in ERVR (11.5 ± 4.4 vs. 12.8 ± 3.8 
mmHg/min/ml, p < 0.05) to study end. In contrast, BQ-123 produced a striking increase 
in ERBF (365.2 ± 103.6 ml/min, p < 0.01 vs placebo), and a reduction in ERVR (-3.0 ± 
0.9 mmHg/min/ml, p < 0.01 vs placebo). There were no significant changes in GFR with 
either placebo or BQ-123. 
 
Urinary sodium and protein excretion (Figure 4.2c & 4.3) 
Placebo had little effect on sodium excretion, whereas BQ-123 produced a marked 
natriuresis with a maximum increase of 35.5 ± 15.4 µmol/min (p < 0.05 vs placebo). 
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Whereas placebo had little effect on urinary protein excretion, BQ-123 led to a sustained 
reduction in proteinuria throughout the time course of the study. This reduction at its 
maximum equated to  -495.7 ± 141.0 µg/min (p < 0.01 vs. placebo), a fall in protein leak 
of about 30%. The size of this effect related to baseline urinary protein excretion with 
subjects with higher baseline proteinuria achieving a greater reduction (r2 = 0.78, p < 
0.05). This effect was seen across all levels of GFR.  
 
Plasma ET-1 
There were no changes in plasma ET-1 concentrations with either drug or placebo. 
 
Sub-study: nifedipine 10mg  
12 subjects were initially randomised to placebo or BQ-123 alone, after which 10 
subjects took part in a randomised 3-way crossover sub-study, which included placebo, 
BQ-123 and nifedipine. All 10 subjects completed the 3 phases of the sub-study without 
adverse events. Subject demographics are shown in Table 4.1 with baseline parameters 
shown in Table 4.2. 
 
BQ-123 and nifedipine produced a similar reduction in MAP (Figure 4.4a). Nifedipine 
caused an initial increase in heart rate (mean increase of 10 beats per minute from 
baseline) that returned to baseline by 60 min. Despite the consistent changes in systemic 
haemodynamics, BQ-123 reduced arterial stiffness to a greater extent than did nifedipine 
(PWV: -0.6 ± 0 vs. -0.3 ± 0.1 m/s, p < 0.001, Figure 4c). BQ-123 and nifedipine also 
increased ERBF to a similar degree (Figure 4.4b), and produced a similar natriuresis (at 
maximum, BQ-123: 64.4 ± 37.4 µmol/min, nifedipine: 37.2 ± 33.8 µmol/min). By 
contrast to BQ-123, nifedipine was associated with a gradual increase in urinary protein 
excretion (at maximum 190.4 ± 142.4 µg/min, p < 0.01 vs placebo, Figure 4.4d), 
whereas BQ123 produced a consistent reduction in proteinuria.  
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Figure 4.1: Systemic haemodynamics and arterial stiffness after ETA receptor 
antagonism. MAP: mean arterial pressure; SVRI: systemic vascular resistance index; 
PWV: pulse wave velocity. Values are given as mean % change from baseline ± SEM 
(left), and mean area under curve (AUC) of % change from baseline ± SEM (right). Blue 
line/block, placebo; red line/block, BQ-123. +p < 0.05 vs. placebo, p < 0.01 vs. 
placebo, *p < 0.001 vs. placebo (ANOVA plus Bonferroni correction for significance at 



















Figure 4.2: Renal haemodynamics and UNaV after ETA receptor antagonism. RBF: 
renal blood flow; RVR: renal vascular resistance; UNaV: sodium clearance. Legend as 




















Figure 4.3: Protein excretion after ETA receptor antagonism. Values are given as mean 
% change from baseline ± SEM (left), and mean area under curve (AUC) of % change 
from baseline ± SEM (right). Blue line/block, placebo; red line/block, BQ-123. +p < 
0.05 vs. placebo, p < 0.01 vs. placebo, *p < 0.001 vs. placebo (ANOVA plus 
Bonferroni correction for significance at specific time points). Figure 4.3c: effect of 











Figure 4.4 (overleaf): Systemic and renal haemodynamics, arterial stiffness and protein 
excretion after ETA receptor antagonism and nifedipine 10mg. Values are given as mean 
placebo-corrected % change from baseline ± SEM (left) and mean area under curve of 
placebo-corrected % change from baseline ± SEM (right). Green line/block, nifedipine; 
red line/block, BQ-123. +p < 0.05 vs. nifedipine, p < 0.01 vs. nifedipine, *p < 0.001 vs. 
nifedipine (ANOVA plus Bonferroni correction for significance at specific time points). 
Protein excretion 
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We have demonstrated for the first time that selective ETA receptor antagonism reduces 
BP, proteinuria and arterial stiffness in patients with varying degrees of proteinuric 
nephropathy, and that these effects are seen on top of optimal treatment with ACE 
inhibitors and ARBs. Importantly, the reductions in proteinuria and arterial stiffness are 
greater than those expected with BP reduction alone. These findings suggest a potential 
role for ETA receptor antagonism in conferring longer-term cardiovascular and renal 
protection in patients with CKD. 
 
The current study confirms the importance of ET-1, acting through the ETA receptor, in 
maintaining the increased vascular tone seen in CKD. BQ-123 produced a fall in BP that 
was associated with systemic vasodilatation, as reflected by the reduction in SVRI. 
However, we observed no change in heart rate suggesting no reflex activation of the 
sympathetic nervous system, in keeping with previous acute studies213. There are only 
two studies of the longer term antihypertensive effects of ET receptor antagonism.  
These suggest that both selective ETA214 and mixed ETA/B antagonists65 are effective at 
reducing BP, but neither study included patients with CKD. Furthermore, both studied 
untreated hypertensive patients. Our current data suggest that, at least in patients with 
CKD, where BP control is often difficult, ET receptor antagonism may provide a novel 
strategy to lower BP to a greater extent than that achieved with existing treatments. 
 
BQ-123 also significantly reduced PWV compared to placebo. This effect is likely to be 
due largely to the reduction in BP seen with BQ-12390. However, PWV continued to fall 
at the end of the study even when BP had returned to baseline. Furthermore, when the 
antihypertensive effect of BQ-123 was matched with nifedipine, the reduction in arterial 
stiffness was significantly greater with BQ-123. Although nifedipine did cause an 
expected increase in heart rate, which may have a minor impact on PWV215, 216, this had 
returned to baseline within an hour of study start and before the measurement of PWV. 
These observations suggest that the effects of ETA receptor antagonism on arterial 
stiffness seen here are not accounted for by changes in BP alone. There are few clinical 
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trials to date demonstrating that differential lowering of PWV with medical treatment 
results in different cardiovascular or renal outcomes88, 217 but the importance of such 
studies is underscored by epidemiological data that suggest that PWV is an independent 
risk factor for CVD morbidity and mortality87, 218, 219. Karalliedde et al recently showed a 
BP-independent reduction in PWV with valsartan compared to amlodipine in patients 
with type 2 diabetes and proteinuria220. Our current data suggest that ETA receptor 
antagonism may reduce arterial stiffness even further in patients established on blockers 
of the renin-angiotensin system and, similarly, in a BP-independent manner.  
 
The mechanism for a BP-independent effect of ETA receptor antagonism on arterial 
stiffness remains unclear. One plausible explanation relates to the balance between the 
ET and nitric oxide (NO) systems. Both ET-1 and NO are vasoactive mediators released 
by the endothelium. However, whereas ET-1 increases PWV96, NO reduces it91 and, in 
animal models, ET receptor antagonism is associated with an up-regulation of activity in 
the NO system79, 80, 83. Thus, in the current study, in addition to the effects of BP lowering 
on arterial stiffness, BQ-123 may have increased NO availability and so reduced arterial 
stiffness. However, the effects of ETA receptor antagonism on endothelial function, as 
assessed by FMD, were less impressive, although there was a trend towards 
improvement.  
 
ETA receptor antagonism increased renal blood flow in association with a reduction in 
renal vascular resistance, suggesting that ET-1, acting through ETA receptors, is involved 
in the increased renovascular tone seen in CKD. We observed no significant changes in 
GFR but we did, as in previous studies53, 221, see a fall in filtration fraction (-7% at 
maximum; data not shown), suggesting that ET-1 induces an ETA receptor mediated 
vasoconstriction, preferentially affecting the efferent arterioles, although not excluding 
an effect on mesangial cells and filtration coefficient. Our observations are consistent 
with animal data35 and raise the possibility that ET-1 promotes hyperfiltration, with its 
consequent potential for renal injury. Consistent with a reduction in filtration fraction, 
BQ-123 produced a sustained reduction in urinary protein excretion that was only 
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beginning to slow at the end of the study. As with the reduction in arterial stiffness, the 
reduction in proteinuria continued even when the antihypertensive effect of BQ-123 had 
waned and BP had returned to baseline, suggesting of a BP-independent effect. Our 
control drug, nifedipine, closely matched both the decrease in BP and increase in renal 
blood flow seen with BQ-123. Nifedipine acts predominantly at the afferent arteriole, 
and so, as expected, produced steady increases in both GFR (7 ml/min at maximum; data 
not shown) and proteinuria throughout the study period. As BQ-123 had little effect on 
GFR and substantially reduced filtration fraction and proteinuria over the same time 
scale as the increase in renal blood flow, these findings are consistent with preferential 
dilation at the efferent arteriole, similar to, and on top of, that seen with ACE inhibitors. 
 
The reduction in proteinuria seen here was related to baseline proteinuria, with subjects 
with a higher level of baseline proteinuria achieving greater reductions. This effect was 
seen across the range of GFRs. This is similar to the effects seen with ACE inhibitors119, 
120, 203. Proteinuria reduction is important both for reducing risk of CKD progression119, 120, 
203 and consequent CVD222. Futhermore, the greater the proteinuria reduction, the lower 
these risks120, 223. Despite maximum achievable renin-angiotensin system blockade, many 
patients with proteinuric CKD have significant residual proteinuria206. Importantly, in 
this study, all subjects were established on treatment with ACE inhibitors, with the 
majority also taking ARBs. The ET and renin-angiotensin systems are known to 
interact142, and a synergistic effect, in terms of systemic haemodynamics, has been 
demonstrated between ETA receptor antagonism and both ACE inhibition211 and 
angiotensin AT1 receptor antagonism52 in humans. Our data suggest ETA receptor 
antagonism can produce a further reduction in proteinuria of ~30% on top of that 
achieved with optimal treatment with inhibitors of the renin-angiotensin system. If 
maintained longer term this should reduce both CKD progression and CVD morbidity 
and mortality.  
 
BQ-123 produced a significant natriuresis that, if maintained, equated to about 50 
mmol/24h. This is likely to be mainly due to the increase in renal blood flow seen with 
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ETA receptor antagonism. Indeed, nifedipine which caused a similar change in renal 
haemodynamics, also caused natriuresis. In addition, all subjects showed a net diuresis, 
even with placebo, a likely consequence of the protocol used. These are important 
observations if ET receptor antagonists are to be used in trials involving CKD patients, 
in whom salt and water retention is an issue.  
 
The current data support a role for ETA receptor antagonism as a novel and worthwhile 
therapeutic target in CKD. As limitations, ours were acute studies and it is important to 
confirm that these effects are maintained longer term. Furthermore, we studied a 
relatively homogeneous CKD population and further work is needed in a broader 
population of patients with CKD, including those with diabetes, vasculitis and renal 
vascular disease. Finally, our choice of active control agent was based, most 
importantly, on the need for the drug to match the antihypertensive profile of BQ-123, to 
produce a similar change in renal haemodynamics, and to be a clinically tolerable agent 
that is also a standard treatment in CKD patients. Although we investigated other agents, 
nifedipine was the only drug to fulfill all these criteria. In summary, our current data 
support a role for selective ETA receptor antagonism as a potential therapeutic approach 




The pharmacokinetic profile of sitaxsentan, a 
selective endothelin-A receptor antagonist, in 





Sitaxsentan is an oral selective endothelin type A receptor antagonist. The aim of this 
study was to investigate the pharmacokinetic profile of a single 100 mg dose in subjects 
with normal and impaired renal function. 
 
Methods 
This was an open label, single oral dose study in subjects with normal and reduced 
glomerular filtration rate, as assessed by 24 hour creatinine clearance (CrCl). Normal 
GFR was defined as a CrCl ≥80 ml/min, mild chronic kidney disease (CKD) as a CrCl 
51-80 ml/min, moderate CKD CrCl 31-50 ml/min, and severe CKD CrCl ≤30 ml/min). 
All subjects received a dose of 100 mg sitaxsentan. 
 
Results 
24 subjects were enrolled, 6 in each of the 4 groups. The mean plasma sitaxsentan 
concentrations were comparable across the groups as were the mean values for Cmax 
(10.3-13.9 µg/ml), AUC∞ (18.7-22.5 h.µg/ml), oral clearance (CL/F, 82.3-94.9 ml/min), 
volume of distribution (Vz/F, 64.8-69.6 l), and elimination half-life (t1/2, 8.6-9.6 h). 
There was substantial overlap among the four groups in the individual subject values for 
CL/F and Vz/F and no relationship between either of these parameters and CrCl. 
 
Conclusion 
After a single 100mg oral dose of sitaxsentan there were no differences in its 
pharmacokinetics among subjects with normal or impaired renal function. 
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Introduction 
Since over 50% of the administered dose of sitaxsentan is excreted via the kidneys, 
impaired renal function could potentially affect the pharmacokinetics of sitaxsentan. We 
therefore evaluated the effect of impaired renal function on the pharmacokinetics of total 
sitaxsentan following a single oral dose of sitaxsentan at the recommended human 
therapeutic dose of 100 mg.  This may be an important issue because ETA receptor 




Male or female subjects, 18 to 65 years old, who were willing and able to provide written 
informed consent, were eligible for inclusion in the study. All subjects with known or 
suspected ischaemic heart disease, elevated liver enzymes (aspartate transaminase and 
alanine transaminase) >3 times the upper end of the reference range, positive results for 
hepatitis B, C or the human immunodeficiency viruses, history of drug or alcohol abuse, 
significant blood loss or donation (>480 ml) within 30 days of the study, a history of organ 
transplantation, the presence of the nephrotic syndrome, or who had taken other 
investigational medication within 1 month of the study medication, were excluded from the 
study. Additionally, all subjects were required to be surgically sterile or using effective birth 
control. Pregnant or lactating women were excluded. Subjects taking any medications 
known to interact with sitaxsentan (those drugs metabolised by cytochrome P450, CYP2C9, 
for example, macrolide antibiotics, phenytoin were excluded). 
 
Subjects were allocated to a group on the basis of creatinine clearance (CrCl) calculated 
from serum creatinine concentration during the screening period using the Cockcroft and 
Gault equation158. Subjects with CrCl ≥80 ml/min were classified as ‘normal’. Subjects with 
‘mild’, ‘moderate’ and ‘severe’ CKD had a CrCl of 51-80 ml/min, 31-50 ml/min, and ≤30 





This was an open label, single oral dose study in subjects with normal and impaired 
renal function. All subjects received a dose of 100 mg sitaxsentan after an overnight fast.  
 
The study was performed at two centres, the Clinical Research Centre, University of 
Edinburgh and DaVita Clinical Research, Minneapolis. The study was approved by the 
Lothian NHS board Scotland and the Human Subjects Research Committee, Hennepin 
County Medical Center, Minneapolis, USA. 
 
Safety assessments included the incidence of adverse events, clinical laboratory test 
results, haemodynamic parameters, electrocardiogram, changes in physical examination 
assessments from baseline, and the monitoring of concomitant medications. 
 
Sample collection and analysis 
Blood samples for the measurement of plasma concentration of sitaxsentan were collected 
prior to and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24 (day 2), 36 (day 2), 48 (day 
3), and 72 (day 4) hours after dosing. As described in Chapter 2, plasma concentrations of 
sitaxsentan were measured using a validated LC/MS/MS method. The (LLOQ) for 
sitaxsentan using this method was 0.005 µg/mL. The percent unbound sitaxsentan (FU) in 
each sample was calculated according to FU = 100% x (CU/CT) where CU and CT represent 
the unbound and total concentrations, respectively. 
 
Pharmacokinetic and statistical analysis 
Pharmacokinetic parameters for sitaxsentan were calculated using non-compartmental 
analysis. Only plasma concentrations greater than or equal to the lower limit of quantitation 
(LLOQ) for the assays were used in the pharmacokinetic analyses. Actual blood sampling 
times were used in all pharmacokinetic analyses. Per protocol times were used to calculate 
mean plasma concentrations for graphical displays. 
 
 92 
Maximum observed plasma drug concentration (Cmax) and time to maximum observed 
plasma drug concentration (Tmax) were taken directly from the data. The elimination rate 
constant (λz) was calculated as the negative of the slope of the terminal log-linear 
segment of the plasma concentration-time curve. The range of data to be used for each 
subject and treatment was determined by visual inspection of a semi-logarithmic plot of 
concentration vs. time. Elimination half-life was calculated according to the following 
equation, t1/2 = 0.693/λz. Area under curve to the last time with a concentration equal to 
or greater than the validated LOQ of the bioanalytical method (AUC0-t) was calculated 
using the linear trapezoidal method and extrapolated to infinity (AUC∞) according to 
AUC∞ = AUC0-t + (Ctf/λz), where Ctf is the final concentration ≥ LOQ. Apparent total 
body clearance after oral dosing (CL/F) and volume of distribution (Vz/F) were 
calculated according to CL/F = dose / AUC∞, and VZ/F = dose / (λz x AUC∞), 
respectively. All pharmacokinetic calculations were done using SAS® for Windows® 
Version 9.1. 
 
The pharmacokinetic parameters Cmax, Tmax, AUC∞, t1/2, CL/F, and Vz/F were compared 
among renal function groups using an analysis of variance (ANOVA) model with renal 
function group as the classification variable.  Cmax and AUC∞ were natural log-
transformed prior to analysis; all other parameters were analysed on the original scale. 
 
Relationships between CL/F and Vz/F and renal function as measured by CrCl were 




A total of 24 subjects took part in the study, 15 males and 9 females. All subjects 
completed the study. There were 6 subjects in all four CrCl groups. Mean (range) of age, 
weight, serum creatinine and CrCl for the four groups are shown in Table 5.1.  
 
 93 





















(47 – 59) 
 
57  
(41 – 66) 
 
49  
(38 – 58) 
 
54  















(68 – 80) 
 
54 
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(71 – 182) 
219 
(151 – 315) 
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67 
(61 – 78) 
 
39 
(31 – 46) 
22 




As illustrated in Figure 5.1 (semi-logarithmic axes), the mean plasma sitaxsentan 
concentrations were comparable across the four renal function groups as were the mean 
values for Cmax, AUC∞, CL/F, Vz/F, and t1/2 (Table 5.2). There were no significant 
differences in these parameters amongst renal function groups (p > 0.05). There was 
little difference in FU among the four renal function groups (Table 5.2). There was 
substantial overlap among the four renal function groups in the individual subject values 
for CL/F and Vz/F and no relationship between either parameter and CrCl, indicating no 
effect of renal impairment on the pharmacokinetics of sitaxsentan (Figures 5.2 and 5.3).  
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Table 5.2: Summary of sitaxsentan pharmacokinetic parameters after oral 
administration of a single 100mg dose to subjects with normal and impaired renal 
function. Results are presented as mean ± standard deviation except for Tmax for which 






















13.9 ± 3.12 
 
11.6 ± 4.01 
 
10.3 ± 4.45 
 

























21.8 ± 9.59 22.5 ± 8.64 18.7 ± 6.26 20.8 ± 10.2 0.3265 
T1/2 (h) 9.0 ± 1.2 9.6 ± 1.1 
 




84.5 ± 34.7 82.3 ± 38.2 94.9 ± 37.3 88.0 ± 30.7 0.9310 



























































Figure 5.1: Mean plasma concentrations of sitaxsentan after oral administration of single 










Figure 5.2: Relationship between CL/F and CrCl after oral administration of single 






r2 = 0.0255 
p = 0.4560 
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Figure 5.3: Relationship between Vz/F and CrCl after oral administration of single 












r2 = 0.0156 
p = 0.5610 
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Discussion 
In this open label, two-centre study to determine the effects of renal impairment on the 
pharmacokinetics of sitaxsentan following a single 100 mg oral dose we have shown that 
plasma sitaxsentan concentrations were very similar between groups separated on the basis 
of CrCl. Furthermore, there was no apparent relationship between any of the sitaxsentan 
pharmacokinetic parameters and increasing renal impairment (Table 5.2).  
 
Although initially licensed for the orphan area of primary pulmonary hypertension the 
indications for ET receptor antagonists are now expanding to include conditions such as 
scleroderma that may cause both pulmonary and renal disease224. Additionally, there is 
increasing interest in the ET system and its antagonism as a potential therapeutic target 
in CKD181. It is therefore, important to understand the pharmacokinetics of such drugs in 
the CKD population. Clinically, altered drug pharmacokinetics may require changes in 
drug dosing and/or frequency of dosing. The results of this study will inform dosing in 
any future studies in CKD, as it is clear that no dosing adjustment for sitaxsentan is 
required for declining glomerular filtration rate based on these pharmacokinetic findings 
for sitaxsentan.  
 
The range of renal impairment in this study, as measured by Cockcroft and Gault CrCl, 
encompassed the full spectrum of CKD, allowing us to confidently state that sitaxsentan 
pharmacokinetics are unchanged. However, we are unable to comment on the degree of 
accumulation of sitaxsentan metabolites in renal impairment, and the potential 
therapeutic and toxicological consequences of this. Furthermore, study subjects had 
serum albumin concentrations that were within the normal range, and the nephrotic 
syndrome was a specific exclusion criterion. This is important as sitaxsentan is highly 
protein-bound (>99.5%), so the nephrotic syndrome may significantly increase free 
plasma drug concentrations. Finally, no patients established on dialysis were included in 
the study. One would not expect this population of patients, however, to have altered 
sitaxsentan pharmacokinetics, because the high degree of protein binding of drug would 
substantially limit clearance by dialysis.  
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Finally, although plasma concentrations of sitaxsentan did not vary significantly we 
cannot comment on whether the pharmacodynamics of ET system antagonism were 
affected similarly through the range of CKD. Increased activity of the ET system is 
recognised in CKD, and antagonism of ET in these patients may lead to beneficial 
cardiovascular and renal effects such as lowering of blood pressure, natriuresis and 
reduction in proteinuria181. If clinical trials using sitaxsentan, and ET antagonists more 




 Chapter 6 
 
Selective endothelin-A receptor antagonism 
reduces proteinuria, blood pressure & arterial 





Background: We have shown that acute selective endothelin-A (ETA) receptor 
antagonism reduces proteinuria, BP and arterial stiffness - key independent, surrogate 
markers of CKD progression and CVD risk, in patients with proteinuric CKD. We 
therefore examined if these effects are maintained longer term using the selective ETA 
receptor antagonist sitaxsentan.  
 
Methods: In a randomised double-blind, 3-way crossover study, 27 subjects receiving 
recommended renoprotective treatment, received 6 weeks of placebo, sitaxsentan 100mg 
od and nifedipine LA 30mg od. 24h proteinuria, protein:creatinine ratio (PCR), 24h 
ambulatory BP, and pulse wave velocity (PWV; as a measure of arterial stiffness), were 
measured at baseline and week 6 of each treatment period. In 13 subjects, renal blood 
flow and glomerular filtration rate were assessed at baseline and week 6 of each period. 
 
Results: Compared to placebo, sitaxsentan significantly reduced proteinuria (24h 
proteinuria by -0.62±0.11g/d, p<0.01; PCR by -43±8mg/mmol, p=0.01), BP (24h mean 
arterial BP by -4±6mmHg, p<0.01), and PWV by -5±9% (p<0.01). Nifedipine matched 
the BP and PWV reductions seen with sitaxsentan, whereas sitaxsentan reduced 
proteinuria and nifedipine did not. Sitaxsentan alone reduced both glomerular filtration 
rate and filtration fraction. It caused no clinically significant side effects. 
 
Conclusions: Sitaxsentan may provide additional cardiovascular and renal protection by 
reducing proteinuria, BP and arterial stiffness in CKD subjects already receiving optimal 
recommended treatment. The antiproteinuric effects of sitaxsentan likely relate to 
changes in BP and renal haemodynamics.  
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Introduction 
We have shown that acute selective ETA antagonism reduces proteinuria and arterial 
stiffness in those with non-diabetic proteinuric CKD. Importantly, these effects were not 
accounted for by BP reduction alone and were evident on top of standard treatment with 
ACE inhibitors and/or ARBs. The aim of the current study was to evaluate whether the 
oral ETA receptor antagonist, sitaxsentan, currently available for the treatment of 
pulmonary artery hypertension, is able to reduce proteinuria, BP and arterial stiffness 




We enrolled subjects 18-70 years of age with stable CKD stages 1 to 4201 and proteinuria 
(>300 mg/day). Subjects were on treatment with ACE inhibitors and/or ARBs for their 
proteinuria (Table 6.1). Explicitly, doses of one or both of drugs were titrated to the 
maximum tolerated, dependent on BP, renal function, serum potassium levels and side 
effects. All medications were unchanged over the 3 months preceding the studies.  
 
Patients with significant co-morbidity, including diabetes mellitus, heart or lung disease, 
and peripheral vascular disease were excluded. To enhance homogeneity and avoid other 
influences on vascular reactivity, patients with vasculitis, other systemic inflammatory 
disease, polycystic kidney disease, and nephrotic syndrome were excluded. Furthermore, 
we excluded patients with abnormal liver enzymes, haemoglobin <8 g/dl, and women of 
childbearing potential.  
 
Thirty-three patients with stable proteinuric CKD were screened, and 27 were recruited 
into the studies.  
 
Study protocol 
This was a single centre, 3-phase randomised, double-blind, placebo-controlled 
crossover study. Its purpose was to investigate the safety, tolerability and efficacy of 
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sitaxsentan 100mg once daily (od) versus placebo on reduction of proteinuria (primary 
endpoint), BP and arterial stiffness (co-secondary endpoints) in subjects with CKD. As 
previous studies with ET receptor antagonists have shown a reduction in BP65, 214, and as 
BP reduction may contribute to changes in protein excretion and arterial stiffness, 
nifedipine LA 30mg od was used as an open-label active control. Our choice of active 
control agent was based, most importantly, on the need for the drug to match the 
antihypertensive profile of sitaxsentan and to be a clinically tolerable agent that is also a 
standard treatment in CKD patients225. A sub-study evaluated the effects of sitaxsentan 
100mg od, placebo, and nifedipine LA 30mg od on renal haemodynamics.  
 
Subjects were randomly assigned to receive sitaxsentan 100 mg, matched placebo, or 
nifedipine LA 30mg, once daily for 6 weeks in addition to their usual medications. Each 
phase was separated by a minimum 2 weeks washout period. Proteinuria, BP and arterial 
stiffness were assessed at baseline, week 3 and week 6 of each treatment period (Figure 
6.1). Proteinuria was assessed using both the mean 24h protein excretion and the mean 
protein:creatinine ratio of 3 consecutive 24h urine collections. Ambulatory BP was 
recorded at the brachial artery using a validated Spacelabs 90217 ambulatory BP 
monitor171. Measurements were taken every 30m for 24h and mean systolic (SBP), mean 
arterial pressures (MAP) and diastolic (DBP) calculated. As measures of arterial 
stiffness, pulse wave velocity (PWV) and central augmentation index (cAIx) were 
recorded90 and assessed pre-dose. Safety data were obtained at baseline and weeks 1, 2, 
3, 4 and 6 for each treatment period. These included ‘office’ BP, weight, haemoglobin, 
haematocrit, liver enzymes, serum potassium and side effects. 
 
Renal function sub-study 
For those subjects taking part in the sub-study, PAH and inutest clearances were used to 
assess renal blood flow and GFR, respectively, at baseline and week 6 of each of the 3 
study periods.  
 
Plasma ET-1 
Plasma ET-1 was measured at baseline, week 3 and week 6 of each treatment period.  
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Data and statistical analysis 
Data were stored and analysed using SAS® Version 8.2 or higher. The planned sample 
size was based on logistical and clinical considerations. The approximate target was a 
total of 30 subjects to be enrolled in the main study, with around 15 of these to be 
included in the sub-study, with the aim of 24 and 12 subjects, respectively, completing.  
 
For efficacy endpoints, the change from baseline to week 6, and from baseline to week 
3, was calculated using analysis of covariance (ANCOVA). The ANCOVA model was 
implemented with terms for treatment group (fixed effect, categorical variable), baseline 
value (fixed effect, continuous variable, as appropriate for the endpoint), period effect 
(fixed effect, categorical variable), and subject effect (random effect, categorical 
variable). Restricted Maximum Likelihood (REML) estimates for the treatment 
differences (sitaxsentan 100 mg minus placebo, sitaxsentan 100 mg minus nifedipine LA 
30 mg, and nifedipine LA 30 mg minus placebo), the associated standard error and p 
value were calculated. The assumptions of the ANCOVA model were checked by 
investigation of a normal probability plot of standardised residuals and a plot of 
standardised residuals versus fitted values. Differences between the least squares means, 
standard errors and p values are presented. Statistical analysis of percentage change from 
baseline was performed similarly. 
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Table 6.1: Individual subject characteristics. Doses are total per day. IgAN: immunoglobulin A nephropathy; FSGS: focal & 

















































2 IgA nephropathy 1.85 
 
1.50 124 84 Lisinopril  
10mg 
 
- Simvastatin 20mg  
3 Reflux nephropathy 2.15 
 
4.05 134 87 Ramipril  
10mg 
 
- Ciprofloxacin 100mg  
Zopliclone 7.5mg  
Ibuprofen 400mg (once) 
Simvastatin 10mg  









1.38 130 74 Enalapril  
30mg 
- Ibuprofen 400mg (once) 
5 IgA nephropathy 3.70 
 




6 IgA nephropathy 2.23 
 
0.43 112 67 Lisinopril  
10mg 




























Ferrous Sulphate 600mg 
 
8 IgA nephropathy 2.03 
 
1.30 119 85 Lisinopril  
40mg 




9 Unknown 1.04 
 
0.50 125 78 - - Pseudoephedrine 60mg (once) 
 
10 FSGS 1.48 
 
5.46 109 68 Lisinopril  
20mg 
















12 IgA nephropathy 4.27 
 
2.59 129 79 Ramipril  
2.5mg 
- Erythropoetin 4000IU 
Alfacalcidol 0.25mcg 
Atorvastatin 20mg 


























Sodium Bicarbonate 2g 
 
14 IgA nephropathy 1.24 
 
0.64 139 77 - Candesartan 
4mg 
Rosuvastatin 5mg 




15 IgA nephropathy 1.73 
 
0.50 122 74 Lisinopril  
20mg 
- Simvastatin 20mg 
Indapamide 2.5mg 
 
16 FSGS 2.70 
 




Salbutamol 200mcg PRN 
Beclamethasone 200mcg 
 
17 IgA nephropathy 1.56 
 







18 FSGS 1.33 
 
5.37 129 76 Ramipril  
5mg 















20 FSGS 1.34 
 
0.47 139 89 Ramipril  
10mg 









0.82 112 76 - - Stemetil 5mg 
Sumatriptan 50mg 
 
22 IgA nephropathy 0.98 
 





0.15 106 72 Ramipril  
10mg 
Irbesartan 
300 mg,  
Doxazosin 4mg 
Hydrochlorothiazide 12.5 mg 




24 FSGS 0.92 
 









Folic Acid 5mg 
Omeprazole 20mg 
Ferrous sulphate 600mg 
 
25 IgA nephropathy 1.38 0.27 116 74 Lisinopril  
40mg 
- Simvastatin 10mg 
Fish Oil,  
Colchicine 1500mcg 








































All 27 subjects completed all 3 phases of the study. Patient diagnoses were IgA 
nephropathy (n = 14, 52%), focal segmental glomerulosclerosis (n = 6, 22%), 
membranous nephropathy (n = 3, 11%), hypertensive nephrosclerosis (n = 2, 7%), reflux 
nephropathy, microhaematuria of presumed glomerular origin (n = 1, 4%, for both) and 
one subject with an unknown cause for their CKD. Subject baseline parameters are 
shown in Table 6.2. For all subjects, baseline parameters did not differ between the 3 
study phases. Individual subject characterisation is provided in Table 6.1. 
Safety data obtained at baseline, week 1, 2, 3, 4 & 6 
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Table 6.2: Baseline patient characteristics for main study and sub-study. Values are 
given as mean of 3 baseline pre-treatment periods ± SD. GFR: glomerular filtration rate; 
PCR: protein:creatinine ratio; PWV: pulse wave velocity; cAIx: central augmentation 




Main study (n = 27) 
 
 






























Body mass index, kg/m2 
 















125 ± 12 
 
78 ± 7 
 









127 ± 10 
 
80 ± 8 
 









Serum potassium, mmol/l 
 
153 ± 75 
 
54 ± 26 
 
136 ± 18 
 
4.6 ± 0.4 
 
152 ± 67 
 
55 ± 26 
 
132 ± 16 
 





4.6 ± 0.8 
 
4.4 ± 1.0 
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ACE inhibitor + ARB 
 













2.03 ± 1.7 
 





8.3 ± 2.4 
 
























2.01 ± 1.6 
 





7.4 ± 1.4 
 


























Main study (n = 27, Table 6.3) 
 
Sitaxsentan vs. placebo 
 
Proteinuria (Figures 6.2a, b & c) 
Placebo was associated with no changes in 24h urinary protein excretion or PCR from 
baseline to week 6. Sitaxsentan, however, significantly reduced both 24h proteinuria and 
PCR by ~30% by study end. These effects of sitaxsentan on proteinuria were apparent at 
week 3 of the study period (24h proteinuria: 2.07 ± 0.34 vs. 1.35 ± 0.22 g/d; PCR: 157 ± 
28 vs. 110 ± 21 mg/mmol, p < 0.01 for both).  
 
Sitaxsentan reduced proteinuria by 25% or more in 19 out of 27 (70%) subjects, and by 
40% or more in 9 out of 27 (33%) subjects. Only 2 subjects failed to show a reduction in 
24h urine protein excretion, and only 1 in PCR. Furthermore, the degree of proteinuria 
reduction closely related to the baseline urinary protein excretion with subjects with 
higher baseline proteinuria achieving a greater reduction (r2 = 0.67, p < 0.01). This effect 
was seen across all levels of GFR (data not shown).  
 
Blood pressure (Figures 6.3a, b & c) & arterial stiffness (Figures 6.4a & b) 
Whereas placebo did not affect MAP, SBP, or DBP between baseline and week 6 of the 
study period, sitaxsentan reduced all three parameters by ~ 4 mmHg following 6 weeks 
dosing.  
 
Placebo had no effects on PWV or cAIx over the 6 weeks study period, whereas, 
sitaxsentan reduced both by study end. PWV fell by ~5% compared to baseline, a 
difference of ~ 10% compared to placebo. 
 
Sitaxsentan vs. nifedipine LA 30mg  
Over 6 weeks dosing nifedipine matched the reductions in SBP (-4.9 ± 1.6 vs. -3.6 ± 1.5 
mmHg), MAP (nifedipine vs. sitaxsentan: -3.8 ± 1.1 vs. -3.7 ± 1.0 mmHg), and DBP (-
3.2 ± 1.0 vs. -3.6 ± 1.0 mmHg) seen with sitaxsentan. Despite this, sitaxsentan reduced 
proteinuria to a greater extent than nifedipine (24h proteinuria: -0.6 ± 0.1 vs. 0.0 ± 0.1 
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g/d, p < 0.01; PCR: -43 ± 8 vs. -3 ± 11 mg/mmol, p = 0.01). For sitaxsentan, the 
reduction in proteinuria correlated with the fall in MAP at week 6 (r2 = 0.16, p = 0.04). 
However, there were no relationships for the changes in proteinuria and BP for the 
placebo and nifedipine phases. Whereas PWV fell to a similar degree with nifedipine as 
with sitaxsentan (-0.4 ± 0.2 vs. -0.4 ± 0.2 m/s), nifedipine did not reduce cAIx following 
6 weeks dosing. 
 
All changes in proteinuria, BP and arterial stiffness had returned to baseline before 
starting the next phase of the study (minimum 2 weeks). 
 
Plasma ET-1 




Table 6.3: Main study data at baseline and week 6 of each study period. Values are 
given as pre-dosing baseline ± SEM. PCR: protein:creatinine ratio; MAP: mean arterial 
pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; PWV: pulse wave 
velocity; cAIx: central augmentation index; ET-1: endothelin-1. * p < 0.01, † p = 0.01, + p 

































2.06 ± 0.38 
 
2.00 ± 0.33 
 
2.07 ± 0.34 
 
1.46 ± 0.26* 
 
1.95 ± 0.30 
 






155 ± 31 
 
153 ± 27 
 
157 ± 28 
 
114 ± 23† 
 
155 ± 27 
 






94.6 ± 2.2 
 
94.3 ± 1.7 
 
94.4 ± 1.8 
 
90.7 ± 1.8+ 
 
95.5 ± 2.0 
 






125.4 ± 2.7 
 
124.2 ± 1.9 
 
124.3 ± 2.2 
 
120.7 ± 1.9+ 
 
125.7 ± 2.4 
 






77.9 ± 1.5 
 
77.5 ± 1.2 
 
77.9 ± 1.3 
 
74.3 ± 1.3* 
 
78. 9 ± 1.5 
 
75.7 ± 1.2* 







7.7 ± 0.3 
 
 
20 ± 2 
8.0 ± 0.4 
 
 
20 ± 2 
8.0 ± 0.3 
 
 
20 ± 2 
 
7.6 ± 0.3+ 
 
 
15 ± 2* 
7.9 ± 0.3 
 
 
19 ± 2 
7.6 ± 0.3+ 
 
 





3.6 ± 0.5 
 
3.7 ± 0.6 
 
 
3.6 ± 0.5 
 
3.7 ± 0.5 
 
3.5 ± 0.5 
 
3.5 ± 0.5 
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Figure 6.2: Effects of placebo, sitaxsentan and nifedipine LA 30mg on the co-primary 
endpoints of (A) 24h proteinuria, and (B) protein:creatinine ratio (PCR). Values are 
given as mean % change from baseline ± SEM at week 3 and week 6. Gray block, 
placebo; hashed block, sitaxsentan; black block, nifedipine. * p < 0.001 for sitaxsentan 
vs. both placebo and nifedipine. (C) Effect of baseline protein excretion on maximal 
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Figure 6.3: Effects of placebo, sitaxsentan and nifedipine LA 30mg on 24h (A) mean 
arterial pressure, (B) systolic blood pressure, and (C) diastolic blood pressure. Legend as 



























Figure 6.4: Effects of placebo, sitaxsentan and nifedipine LA 30mg on (A) pulse wave 
velocity, and (B) central augmentation index. Legend as for Figure 1. For (A), * p < 0.01 
and  + p < 0.05 for sitaxsentan and nifedipine vs. placebo. For (B), + p < 0.05 for 

















Renal sub-study (n = 13, Table 6.4 & Figure 6.5) 
ERBF did not change from day 0 to week 6 with placebo, sitaxsentan or nifedipine. 
Whilst GFR was similar at day 0 and week 6 with placebo and nifedipine, sitaxsentan 
produced a substantial fall in GFR by week 6. Effective filtration fraction (EFF) 
remained unchanged between day 0 and week 6 with both placebo and nifedipine. 
However, EFF was lower with sitaxsentan. This was a consistent finding with 12 out of 
13 subjects demonstrating a fall in EFF. 10 subjects had a EFF of >20% at baseline. 
These subjects showed a fall of >2% (range 2.1 – 8.9%) after 6 weeks’ sitaxsentan 
treatment. The 3 subjects with a EFF <20% at baseline showed less impressive 
reductions in EFF following sitaxsentan dosing. All changes in renal haemodynamics 
had returned to baseline before starting the next phase of the study (minimum 2 weeks). 
 
Table 6.4: Renal sub-study data from clearance studies performed at baseline and week 
6 of each study period. Values are given as pre-dosing baseline ± SEM. GFR: 
glomerular filtration rate; ERBF: effective renal blood flow; ERVR: effective renal 
vascular resistance; EFF: effective filtration fraction. * p < 0.01 and + p < 0.05 for 


























56 ± 7 
 
54 ± 8 
 
57 ± 8 
 
48 ± 8+ 
 
59 ± 8 
 





533 ± 66 
 
552 ± 65 
 
511 ± 63 
 
543 ± 73 
 
562 ± 82 
 





230 ± 52 
 
206 ± 39 
 
236 ± 44 
 
232 ± 48 
 
248 ± 58 
 






19.1 ± 1.1 
 
17.9 ± 1.3 
 
20.8 ± 1.0 
 
16.6 ± 0.7* 
 
20.3 ± 1.1 
 
20.5 ± 1.4 
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Figure 6.5: Effect of placebo, sitaxsentan and nifedipine LA 30mg on effective filtration 
fraction (EFF). Individual subject data is presented as well as the mean ± SEM at 
baseline and 6 weeks. 
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Adverse events (Table 6.5) 
There was no difference in the overall incidence of adverse events between the 
sitaxsentan and placebo groups.  Of note, there was no significant weight gain (Figure 
6.6), fall in haemoglobin or haematocrit, or rise in serum potassium associated with 
sitaxsentan treatment compared to placebo.  
 
Table 6.5: Adverse events reported in the study. 
  
Placebo 




(n = 27) 
 
Nifedipine  
(n = 27) 
 



























Discontinuation due to adverse  








Adverse events reported >5%,  
n (%) 
    
   Headache 
 
   Nasal congestion 
 
   Flushing 
    
   Diarrhoea 
    
   Nausea & Vomiting 
    
   Back pain 
    
























































Figure 6.6: Effects of placebo, sitaxsentan and nifedipine on weight. 
% Weight change


























We have demonstrated that sitaxsentan, an oral selective ETA receptor antagonist 
reduces proteinuria, BP and arterial stiffness in patients with varying degrees of 
proteinuric nephropathy. These effects on proteinuria were seen in patients already 
receiving optimal treatment with ACE inhibitors and ARBs, and were at least in part BP 
independent. These findings suggest a potential role for ETA receptor antagonism in 
conferring longer-term cardiovascular and renal benefits in patients with CKD. 
 
In the current study all subjects had renal diagnoses that are classically associated with 
proteinuria and all were established on maximally tolerated treatment with ACE 
inhibitors and/or ARBs with good BP control. Despite this, mean baseline proteinuria 
was still significant at ~2g/d (range 0.3 – 7.8g/d). Importantly, the data presented here 
support a potential role for ET receptor antagonists as a novel class of drug to help 
further reduce proteinuria in these patients on top of standard therapy. This should have 
the capacity to reduce CKD progression, and the associated CVD, morbidity and 
mortality.  
 
We have recently shown that acute ETA receptor antagonism can reduce proteinuria by a 
further ~30% on top of that achieved with optimal treatment with inhibitors of the renin-
angiotensin system in subjects with proteinuric CKD. The current study, in a similar 
cohort of subjects, suggests that these effects are maintained longer term and are of a 
similar magnitude. Interestingly, the size and time course of this effect is similar to that 
seen with blockers of the renin-angiotensin system226-228. Furthermore, of those subjects 
showing ≥ 40% reduction in urinary protein leak (9 of 27), 4 were on dual ACE inhibitor 
/ ARB therapy, supporting a role for ET receptor antagonists as adjunctive treatments for 
CKD patients already established on renin-angiotensin system inhibitors. As has been 
previously shown with ACE inhibitors119, the reduction in proteinuria was related to 
baseline proteinuria, with subjects with a higher level of baseline urinary protein leak 
achieving greater reductions. This effect was seen across the range of renal function.  
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The effects of sitaxsentan on proteinuria described here are likely explained by changes 
in both systemic and renal haemodynamics. As expected, the change in BP following 6 
weeks’ sitaxsentan dosing correlated with the reduction in proteinuria (r2 = 0.16, p = 
0.04), supporting a role for BP reduction in reducing proteinuria. However, sitaxsentan 
also reduces proteinuria through effects that are independent of BP. In the current study 
our active control nifedipine matched the fall in BP seen with sitaxsentan but despite this 
sitaxsentan reduced proteinuria to a greater degree. Furthermore, for the reduction in BP 
seen with sitaxsentan (~4 mmHg) a less impressive fall in proteinuria than the observed 
~30% would be expected. ACE inhibitors which reduce proteinuria by a similar degree 
to the effect seen here with sitaxsentan have more impressive effects on BP, reducing it 
by ~10 mmHg65.  
 
Our current sub study data support a renal haemodynamic mechanism for the reduction 
in proteinuria seen with sitaxsentan. ETA receptor antagonism had no effect on renal 
blood flow or renal vascular resistance. However, as in previous studies53, 221, there was a 
very consistent fall in filtration fraction (-4%), suggesting that ET-1 induces an ETA 
receptor mediated preferential efferent arteriolar constriction. These effects are 
analogous to, and occur in addition to, those seen with renin-angiotensin system 
blockade. This postulated reduction in efferent arteriolar tone with ETA receptor 
antagonism should reduce glomerular perfusion pressure. This will result in a reduction 
in proteinuria with an associated short-term fall in GFR. Consistent with this proposed 
effect, we observed a significant fall in GFR (-9 ml/min) after 6 weeks’ sitaxsentan 
treatment. In patients already prescribed blockers of the renin-angiotensin system these 
effects, despite an initial fall in GFR, should correlate with longer term slowing of the 
rate of CKD progression. 
 
The current study confirms the concept that blocking the ETA receptor reduces BP in 
CKD. Sitaxsentan reduced BP modestly (a fall in MAP of ~4 mmHg). This effect may 
have been more impressive had the subjects not had such good baseline BP control (see 
Table 6.1), which meets current CKD management guidelines204. There are only three 
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studies of the longer term antihypertensive effects of ET receptor antagonism. These 
suggest that both selective ETA214, 229 and mixed ETA/B antagonists65 are effective at 
reducing BP in untreated hypertensive patients or those with resistant hypertension. Our 
current data suggest that, at least in patients with CKD, where BP control is often 
difficult202, ET receptor antagonism may provide a novel strategy to lower BP to a 
greater extent than that achieved with existing treatments.  
 
Sitaxsentan also significantly improved arterial stiffness as measured by PWV and cAIx 
compared to placebo. This is likely to be due largely to the reduction in BP seen with 
sitaxsentan90, a view supported by the similar change in BP and PWV seen with 
nifedipine. Interestingly, despite similar BP effects, sitaxsentan reduced cAIx to a 
greater extent than nifedipine. In the current study, unlike for BP and proteinuria, the 
reductions in PWV and cAIx were higher at 6 weeks’ than after 3 weeks’ sitaxsentan 
treatment. It is possible that longer treatment with an ETA receptor antagonist might 
reduce PWV further, and perhaps to a greater degree than nifedipine. There are few 
clinical trials demonstrating that differential lowering of PWV with medical treatment 
results in different cardiovascular or renal outcomes88, 217 but the importance of such 
studies is underscored by epidemiological data suggesting that PWV is an independent 
risk factor for CVD morbidity and mortality87, 218.  
 
6 weeks’ sitaxsentan dosing in subjects with varying degrees of proteinuric CKD was 
not associated with any more adverse events than placebo. Importantly, we observed no 
weight gain, clinically significant oedema, fall in haemoglobin or haematocrit, or rise in 
serum potassium. Furthermore, the changes in renal haemodynamics were not associated 
with sodium retention (data not shown). Fluid retention has been observed in several 
trials with ET receptor antagonists though its mechanism remains unclear. From a renal 
perspective, the lack of rise in serum potassium with sitaxsentan is clinically significant 
as this is a troublesome side effect with both ACE inhibitors and ARBs limiting their 
use. Indeed, 3 of the 27 subjects studied here were intolerant of either agent due to 
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problematic hyperkalemia, and so selective ETA receptor antagonists may provide an 
alternative proteinuria lowering strategy in such patients. 
 
We recognise some limitations to the current work. The study was crossover by design. 
This may lead to subjects dropping out limiting its power, as well as having the issue of 
carry over effects between different treatment phases. However, we observed no such 
problems here. Furthermore, whilst the small study number is reasonable to show 
benefits of treatment much larger studies are required to highlight potentially important 
but infrequent adverse events. In summary, the current data support a role for selective 
ETA receptor antagonism as a novel and worthwhile therapeutic target in CKD to lower 
proteinuria, BP and arterial stiffness on top of standard treatment, and on this basis, 







The studies presented in this thesis have explored the role of ET-1 in CKD and the 
effects of selective ETA receptor antagonism, both acutely and longer term, in chronic 
proteinuric nephropathy. They have helped establish a clearer picture of ET in renal 
pathophysiology and support a clinical potential for ET receptor antagonists in the 
treatment of renal dysfunction.  
 
Urinary ET-1 in CKD 
The studies in Chapter 3 have shown that plasma and urinary ET-1 concentrations 
increase as renal function declines. Importantly, whereas plasma ET-1 increases linearly, 
urinary ET-1 shows an exponential increase. This suggests that plasma and urinary ET-1 
act as two separate systems. Indeed, this is supported by other data which show that 
when the administration of ET antagonists dynamically affect plasma ET-1, urinary ET-
1 is unaffected183. The prominent rise in urinary ET-1, which is assumed to be of renal 
origin, with declining GFR supports its role as an important mediator of CKD 
development and progression. 
 
We have also shown that urinary ET-1 is a marker of active renal inflammation. Its 
levels being high in those with active, biopsy-proven lupus nephritis, and falling with 
successful immunosuppressive treatment. It would be of great interest to extend these 
findings to other more inflammatory renal diseases such as ANCA-associated vasculitis 
to see if the same holds true. Also, further investigation as to whether the rise in urinary 
ET-1 precedes any obvious clinical or biochemical decline would make it a potentially 
powerful biomarker of disease relapse allowing earlier diagnosis and treatment of 
disease than is currently possible. 
 
The role of ET-1 and the ETA receptor in the maintenance of vascular tone in CKD 
The studies in Chapters 4 and 6 support a role for ET-1 acting via the ETA receptor in 
contributing to systemic and renal vascular tone in patients with CKD. However, 
whereas the fall in BP seen acutely (Chapter 4) is maintained longer term (Chapter 6) the 
increase in renal blood flow is not. This is likely due to adaptive changes in renal 
haemodynamic autoregulatory mechanisms. 
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The current data are in keeping with earlier work where the magnitudes of the BP 
reduction and increase in renal blood flow were similar53. These earlier studies compared 
systemic and renal haemodynamic responses in both health and CKD and suggested that 
the effects of selective ETA receptor antagonism on lowering BP are greater in CKD than 
in health and the increase in renal blood flow is only seen in CKD. Thus, the presence of 
renal failure and (treated) hypertension may alter vascular sensitivity to selective ETA 
receptor antagonists and reflect an enhanced activity of the ET system in renal disease, 
particularly in the renal circulation. The observed increased production of urinary ET-1 
in CKD (Chapter 3) would support this argument, at least in respect of the kidney.  
 
Renoprotective profile of selective ETA receptor antagonism in CKD 
The studies presented here suggest that selective ETA receptor antagonism offers a 
potentially renoprotective profile by reducing both BP and proteinuria. Hypertension is 
an independent risk factor for CKD progression200, and is a frequent finding in patients 
with CKD. Despite treatment with multiple antihypertensive agents the majority of CKD 
patients fail to reach target BP202. Proteinuria is a common feature of CKD and its 
presence is independently associated with an adverse renal outcome203. Current 
treatments for proteinuria focus on BP reduction119. Nevertheless, many CKD patients 
have significant residual proteinuria despite optimal treatment206. Importantly, both the 
reductions in BP and proteinuria seen acutely (Chapter 4) with selective ETA receptor 
blockade are maintained longer term (Chapter 6). 
 
These studies have demonstrated that ETA receptor blockade produces a clinically 
relevant fall in BP in CKD patients. Importantly, this is without sodium retention, 
weight gain or troublesome adverse effects. Interestingly, the subjects studied already 
had excellent BP control, essentially achieving current recommended targets for CKD 
and it may be that if given to those with higher BP and more difficult to control 
hypertension the effects of ETA receptor antagonism may be even more impressive.  
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Whereas the BP lowering effect of ETA antagonism was lower longer term than acutely 
(4 vs. 10 mmHg), the reduction in proteinuria was similar (~30%). Current guidelines 
for treating proteinuria recommend the use of ACE inhibitors230 and angiotensin receptor 
blockers121, both of which are inhibitors of the renin-angiotensin system and thought to 
reduce proteinuria to a greater extent than accounted for by BP-lowering alone205. 
Importantly, the effects seen in the current studies, both acute and chronic, were in 
patients that were optimally treated for their proteinuria in terms of ACE inhibitors 
and/or angiotensin receptor blockers. Thus, selective ETA receptor antagonism offers a 
potentially novel approach to reducing proteinuria in CKD. 
 
Future work 
The observations in this thesis raise further questions to be answered and areas to 
explore. Some of these are discussed below. 
 
1. Selective ETA vs. mixed ETA/B receptor antagonism in CKD 
The studies presented here have used a selective ETA blocking approach. Both selective 
ETA and mixed ETA/B receptor antagonists are now available for clinical use. However, 
there remain few comparative studies of their effects in CKD. It would be of great 
interest to see if the results seen in Chapter 6 (proteinuria, BP and arterial stiffness 
reduction) are similar with a mixed ETA/B blocking strategy. In particular, whether or not 
the side effect profile is as favourable given the theoretical risk of blocking ETB receptor 
mediated natriuresis and so potentially risking fluid retention with a mixed approach. 
 
In acute studies in subjects with CKD, the renal vasodilatation seen with selective ETA 
receptor antagonism is attenuated with additional ETB receptor blockade64, suggesting 
that tonic ETB receptor-mediated renal vasodilatation plays a key role in opposing renal 
vasoconstriction. This is likely to be of particular importance in CKD, where baseline 
renal vascular resistance is high. Conversely, proteinuria reduction is seen with both 
approaches231, 232. Although both approaches may be of benefit in CKD there are no 
head-to-head studies.  
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2. ET receptor antagonism and CKD progression 
We have shown that ET receptor antagonists reduce BP and proteinuria over medium 
term dosing. These data suggest that these agents may attenuate CKD progression. If 
true, this would clearly be of major therapeutic interest and benefit. This would be best 
assessed by long term clinical trials using progression to dialysis or doubling of serum 
creatinine as current validated end points. Whilst there are currently no human data, ET 
receptor antagonists have been shown to attenuate the progression of renal insufficiency 
in a rat remnant-kidney model136. While both selective and mixed ET receptor 
antagonists have produced positive results137, the effect appears to be greater with 
selective ETA receptor antagonism138. Indeed, concomitant administration of an ETB 
receptor antagonist can abolish the beneficial effects of ETA receptor antagonism139.  
 
3. Natriuresis and salt sensitivity 
We clearly demonstrated a natriuresis with ETA receptor antagonism in Chapter 4. This 
may be of particular interest in salt sensitive hypertension, a condition where an 
inability to excrete sodium effectively contributes to hypertension. Animal models of 
salt sensitive hypertension have suggested an important pathogenic role for ET-1233 and 
the therapeutic potential for ETA receptor antagonism in this condition234-236. In man, 
plasma and urinary ET concentrations have been shown to be elevated in salt-sensitive 
individuals237, 238, though this is not a uniform finding70. Examining the effects of ET 
receptor antagonism in two hypertensive groups, one clearly identified as salt sensitive, 
one not, on both high and low salt diets would clarify the role of ET, particularly of 
renal origin in salt sensitivity. Because salt sensitivity may be linked to a blunted 
increase in endothelial nitric oxide (NO) in response to a high salt diet236, the 
comparison of ETA with ETA/B blockade may be interesting in this respect. 
 
4. Interaction of selective ETA receptor antagonists with PDE5 inhibitors 
CKD is associated with a downregulation of the NO system and this contributes to the 
development of hypertension and disease progression239, 240. NO causes vasodilatation by 
stimulating vascular smooth muscle soluble guanylate cyclase to convert guanosine 5’-
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triphosphate to cGMP241, which leads to a reduction in intracellular calcium 
concentration242. cGMP is degraded by cGMP-specific, cGMP-binding 
phosphodiesterase 5 (PDE5), and intracellular concentrations of cGMP are tightly 
controlled by this enzyme via a number of negative feedback mechanisms243. Inhibitors 
of PDE5 increase the intracellular concentration of cGMP and thus promote NO-
mediated cellular responses. 
 
PDE5 inhibitors have been investigated in animal models of CKD where they have been 
shown to reduce BP, proteinuria, inflammation and, importantly, retard CKD 
progression244. There are no human data to date. This would be of great interest given 
that these are currently available licensed drugs. Furthermore, as the ET system works in 
balance with the NO system and ET receptor antagonism restores NO bioavailability, it 
would be worthwhile to compare the effects of PDE5 inhibition both in the presence and 
absence of ET receptor antagonism as there may be additional effects of a combined 
approach. 
 
5. Acute intervention in scleroderma hypertensive crisis 
Scleroderma associated pulmonary arterial hypertension is treated with ET receptor 
antagonism245, 246. Though not directly studied in this thesis, given the vasoactive nature 
of these drugs, and the pro-fibrotic effects of ET-1 experimentally, this condition would 
represent a potential target for ETA receptor antagonists, particularly given that the 
current treatment for this condition is ACE inhibition. 
 
6. The role of the ET system in podocyte and macrophage biology 
We have shown a reduction in proteinuria with selective ETA receptor antagonism. The 
mechanism for this, in part, relates to a reduction in GFR (Chapter 6). However, 
proteinuria is associated with damage to podocytes and the longer term effects of ET 
receptor antagonism may also relate to alterations in podocyte function. Indeed, selective 
ETA receptor blockade is protective in a rodent model of glomerulosclerosis that exhibits 
both podocyte injury and proteinuria247. 
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Glomerular infiltration by macrophages (Mφ) is common in many forms of proteinuric 
nephropathy. Mφ have the potential to cause death of intrinsic renal cells including 
mesangial and tubular cells and this contributes to disease progression248. Mφ are likely 
to interact with podocytes but data are limited. Strategies that reduce the pro-
inflammatory activity of Mφ reduce proteinuria in experimental models249. 
 
There are few data on the role of ET-1 in either podocyte or Mφ biology. Murine 
podocytes exposed to protein de-differentiate and produce ET-1126. Furthermore, 
treatment of these podocytes with exogenous ET-1 induces a similar de-differentiated 
phenotype126. Mφ have been shown to produce ET-1 in response to LPS stimulation250 
and in human monocytes ET-1 stimulation resulted in TNF-α and IL-1β secretion251. It 
would thus be of great interest as a corollary to our clinical studies to address the effects 
of ET-1 on podocyte and Mφ function, to examine how these cells interact, and to assess 
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